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The Double-Edged Sword of Health Care Integration:
Consolidation and Cost Control*
ERIN C. FUSE BROWN AND JAIME S. KING†
The average family of four in the United States spends $25,826 per year on health
care. American health care costs so much because we both overuse and overpay for
health care goods and services. The Affordable Care Act’s cost control policies focus
on curbing overutilization by encouraging health care providers to integrate to promote efficiency and eliminate waste, but the cost control policies largely ignore
prices. This article examines this overlooked half of health care cost control policy:
rising prices and the policy levers held by the states to address them. We challenge
the conventional wisdom that reducing overutilization through health care integration will effectively reduce health spending. We argue that vertical integration
—bringing together disparate providers from hospitals to physicians—is a doubleedged sword, with not only the potential to reduce wasteful and unnecessary use of
services but also downside risks of increasing market consolidation and health care
prices. Due to already highly concentrated health care markets and the limits of federal antitrust enforcement of vertical health care integration, states have both an
opportunity and an obligation to supplement federal antitrust efforts to control rising
health care prices stemming from health care integration. The way to manage the
double-edged sword of health care integration is to require price and quality oversight to avoid harm to competition. We offer a menu of six policy initiatives for states
to choose from, ranging from data collection to rate regulation. If we are to control
our personal and national health care spending, states have a critical role to play in
overseeing health care integration and private health care price increases.
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INTRODUCTION
It is no secret that U.S. health care costs are out of control. The United States has
experienced a more than 400% increase in total annual health care expenditures since
1990,1 exceeding $3 trillion and representing 17.5% of gross domestic product
(GDP) in 2014 alone.2 The average family of four spends $25,826 on health care per
year, an amount that could buy the family a new Toyota Prius or Tacoma every year. 3
Yet while we pay more per capita than any other nation for health care, the health of
American citizens does not reflect this additional spending.
In the lead-up to the passage of the Affordable Care Act (ACA), Atul Gawande
laid out what has become the dominant narrative of U.S. health care cost containment

1. See CTRS. FOR DISEASE CONTROL & PREVENTION, GROSS DOMESTIC PRODUCT,
NATIONAL HEALTH EXPENDITURES, PER CAPITA AMOUNTS, PERCENT DISTRIBUTION, AND
AVERAGE ANNUAL PERCENT CHANGE: UNITED STATES, SELECTED YEARS 1960–2013, tbl.102
(2014), http://www.cdc.gov/nchs/data/hus/2014/102.pdf [https://perma.cc/G4T8-UR67].
2. CTRS. FOR MEDICARE & MEDICAID SERVS., NATIONAL HEALTH EXPENDITURES 2014
HIGHLIGHTS, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports
/NationalHealthExpendData/Downloads/highlights.pdf [https://perma.cc/V2NC-X226].
3. CHRIS GIROD, SUE HART & SCOTT WELTZ, 2016 MILLIMAN MEDICAL INDEX 3 (May
2016), http://us.milliman.com/uploadedFiles/insight/Periodicals/mmi/2016-milliman-medical
-index.pdf [https://perma.cc/7XYA-S834] (“[O]f the typical family of four’s $25,826 in total
[health care] spending, . . . the employer pays 57% of costs, or $14,793, while the employee
pays the other 43%: $6,717 in employee contributions through payroll deduction and $4,316
in the form of out-of-pocket expenses incurred at time of service.”); see TOYOTA,
http://www.toyota.com/#!/hybrids-ev [https://perma.cc/8RX2-6D5N] (listing the starting
price for a 2016 Prius as $19,560) TOYOTA, http://www.toyota.com/#!/trucks
[https://perma.cc/KL37-YC59] (listing the starting price for a 2017 Tacoma as $24,120).
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in his highly influential New Yorker article, The Cost Conundrum.4 The narrative was
this: Medicare health care expenditures vary widely throughout the country in ways
that cannot be explained by the sickness of the patient population, the quality of care
provided, or even the cost of producing the health care. The most expensive regions
in the country have higher health care utilization, and for that extra utilization, they
produce neither better quality care nor better patient health outcomes. In fact, leading
researchers estimate that the federal government could eliminate nearly 30% of
Medicare spending without sacrificing quality or outcomes if higher-spending regions mirrored the utilization patterns of lower-spending regions.5 Following this
logic, Dr. Gawande and several leading health economists argued that to bend the
cost curve, the U.S. health care system needed to realign its payment and delivery
systems to disincentivize and reduce overutilization, and to instead reward coordination, quality, and efficiency. 6 Gawande’s account was so compelling that it became
required reading in President Obama’s White House and Capitol Hill in the months
leading up to the passage of the ACA, heavily influencing the translation of cost
control policies into law.7
As a result, the cost containment mechanisms of the ACA and other recent health
care reform efforts focus heavily on reducing overutilization. 8 To do so, federal policy incentivizes vertical integration among providers at different phases of health
care delivery to improve care coordination, eliminate wasteful or repetitive services,
encourage shared resources, and reduce overhead expenses. 9 Vertical integration in
health care commonly occurs when a hospital purchases a physician practice, making

4. Atul Gawande, The Cost Conundrum, NEW YORKER (June 1, 2009), http://www
.newyorker.com/magazine/2009/06/01/the-cost-conundrum [https://perma.cc/5JHY-4WV4].
5. Id.; see also John E. Wennberg, Elliot S. Fisher & Jonathan S. Skinner, Geography
and the Debate over Medicare Reform, HEALTH AFF. W96, W104 (Feb. 13, 2002),
http://content.healthaffairs.org/content/early/2002/02/13/hlthaff.w2.96.short [https://perma.cc
/V5G6-DW2X].
6. See, e.g., Public Meeting of the Medicare Payment Advisory Commission 309,
380–400 (Nov. 8, 2006), transcript available at http://www.medpac.gov/docs/default
-source/meeting-materials/november-2006-meeting-transcript.pdf?sfvrsn=0 [https://perma.cc
/BB5N-G57L] (describing the ACO model variously as “extended hospital medical staff” and
“accountable organization”); David Cutler, How Health Care Reform Must Bend the Cost
Curve, 29 HEALTH AFF. 1131 (2010); Elliot S. Fisher, Douglas O. Staiger, Julie P.W. Bynum
& Daniel J. Gottlieb, Creating Accountable Care Organizations: The Extended Hospital
Medical Staff, 26 HEALTH AFF. w44 (2007).
7. See Bob Kocher & Farzad Mostashari, Opinion, A Health Care Success Story, N.Y.
TIMES (Sept. 23, 2014), http://www.nytimes.com/2014/09/24/opinion/a-health-care-success
-story.html [https://perma.cc/4CC4-4PLB]; Robert Pear, Health Care Spending Disparities
Stir a Fight, N.Y. TIMES (June 8, 2009), http://www.nytimes.com/2009/06/09/us/politics
/09health.html [https://perma.cc/BF7A-R6L7].
8. Examples include the Medicare Shared Savings Program, 42 U.S.C. § 1395jjj (2012);
the Hospital Value-Based Purchasing Program, 42 U.S.C.A. § 1395ww(o) (West 2015); and
the National Pilot Program on Payment Bundling, 42 U.S.C. § 1395cc-4 (2012).
9. See KAISER FAMILY FOUND., SUMMARY OF THE AFFORDABLE CARE ACT (2013),
http://kff.org/health-reform/fact-sheet/summary-of-the-affordable-care-act [https://perma.cc
/9UMJ-CUK2].
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the resulting entity responsible for both inpatient and outpatient care. Unfortunately,
in this effort to control utilization, we have overlooked the other half of the cost
control equation: prices.10
Health care cost containment efforts must consist of two parts: reducing
overutilization and constraining health care prices.11 Just like going to the grocery
store, the amount of your bill depends on how many items you buy as well as the
price of each item. The United States will not bend the cost curve without addressing
private health care prices.12 High prices are the main reason the United States spends
so much more on health care than other wealthy, developed countries. 13 Moreover,
similar to the overutilization problem, the higher prices we pay do not result in more
or better quality care nor do they lead to better health outcomes. 14 While it may be
true that nearly a third of Medicare spending is waste, 15 when looking at our total
public and private health care spending, price increases explain most of the rise in
U.S. health care costs,16 eclipsing the effects of increasing utilization, the aging or
sickness of the population, the supply of health care services, malpractice litigation,
and defensive medicine.17

10. See Kevin Quealy & Margot Sanger-Katz, The Experts Were Wrong About the Best
Places for Better and Cheaper Health Care, N.Y. TIMES: THE UPSHOT (Dec. 15, 2015), http://
www.nytimes.com/interactive/2015/12/15/upshot/the-best-places-for-better-cheaper-health-care
-arent-what-experts-thought.html [https://perma.cc/9XNR-CJRB] (quoting Robert Berenson,
fellow at the Urban Institute, as saying “[p]rice has been ignored in public policy”).
11. Erin C. Fuse Brown, The Blind Spot in the Patient Protection and Affordable Care
Act’s Cost-Control Policies, 163 ANNALS INTERNAL MED. 871 (2015).
12. See Zack Cooper, Stuart Craig, Martin Gaynor & John Van Reenen, The Price Ain’t
Right? Hospital Prices and Health Spending on the Privately Insured 2–3 (Dec. 2015)
(unpublished manuscript), http://www.healthcarepricingproject.org/sites/default/files/pricing
_variation_manuscript_0.pdf [https://perma.cc/3V7T-LL2X].
13. Gerard F. Anderson, Uwe E. Reinhardt, Peter S. Hussey & Varduhi Petrosyan, It’s
the Prices, Stupid: Why the United States Is So Different from Other Countries, 22 HEALTH
AFF. 89, 103 (2003); Bruce C. Vladeck & Thomas Rice, Market Failure and the Failure of
Discourse: Facing Up to the Power of Sellers, 28 HEALTH AFF. 1305, 1305–06 (2009).
14. See Vladeck & Rice, supra note 13, at 1306.
15. See Wennberg et al., supra note 5, at W104.
16. Gerard F. Anderson, Peter S. Hussey, Bianca K. Frogner & Hugh R. Waters, Health
Spending in the United States and the Rest of the Industrialized World, 24 HEALTH AFF. 903,
904 (2005); Hamilton Moses III, David H. M. Matheson, E. Ray Dorsey, Benjamin P. George,
David Sadoff & Satoshi Yoshimura, The Anatomy of Health Care in the United States, 310
JAMA 1947, 1949 (2013).
17. Anderson et al., supra note 16, at 904; Moses III et al., supra note 16, at 1949 (“Between 2000 and 2011, increase in price (particularly of drugs, medical devices, and hospital
care), not intensity of service or demographic change, produced most of the increase in health’s
share of GDP.”); OFFICE OF ATT’Y GEN. MARTHA COAKLEY, EXAMINATION OF HEALTH CARE
COST TRENDS AND COST DRIVERS 3–4, 16–27, 35 (2010), http://www.mass.gov/ago/docs
/healthcare/2010-hcctd-full.pdf [https://perma.cc/928G-3242] (“Price increases, not increases
in utilization, caused most of the increases in health care costs during the past few years in
Massachusetts.”).
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In the United States, the health care pricing problem is largely a provider market
power problem.18 Within the same geographic area, there can be a 60% difference
between the highest- and lowest-priced hospitals for the same inpatient service, and
a twofold difference in prices for outpatient services. 19 A substantial body of research
demonstrates that market power drives these unwarranted variations in price between
providers, not differences in quality, payer mix, demographics, or health of the patient population.20 In other words, when we pay more at a high-price provider, we
rarely receive more or better care; we simply pay more for its market leverage. 21
Unfortunately, the vertical integration used to target overutilization may also increase provider market leverage.22 The primary vehicle for achieving vertical integration in the ACA is the Accountable Care Organization (ACO), a group of affiliated doctors, hospitals, and other health care providers that cooperate to provide
high-quality, coordinated care to a specific patient population.23 To form an ACO,
provider organizations can integrate clinically, structurally, and/or financially. However, obtaining the desired clinical and financial integration can also open the door
for health care provider organizations to vertically integrate in ways that further consolidate health care markets, increase provider market leverage, and raise prices.

18. See, e.g., PAUL B. GINSBURG, CTR. FOR STUDYING HEALTH SYS. CHANGE, RESEARCH
BRIEF NO. 16, WIDE VARIATION IN HOSPITAL AND PHYSICIAN PAYMENT RATES EVIDENCE OF
PROVIDER MARKET POWER 6 (2010), http://www.hschange.org/CONTENT/1162/1162.pdf
[https://perma.cc/U2XN-HGAH]; CHAPIN WHITE, AMELIA M. BOND & JAMES D.
RESCHOVSKY, CTR. FOR STUDYING HEALTH SYS. CHANGE, RESEARCH BRIEF NO. 27, HIGH AND
VARYING PRICES FOR PRIVATELY INSURED PATIENTS UNDERSCORE HOSPITAL MARKET POWER
2 (2013), http://www.hschange.com/CONTENT/1375/1375.pdf [https://perma.cc/987U-AVYX];
Robert A. Berenson, Paul G. Ginsburg, Jon B. Christianson & Tracy Yee, The Growing Power
of Some Providers To Win Steep Payment Increases from Insurers Suggests Policy Remedies
May Be Needed, 31 HEALTH AFF. 973, 973 (2012); Robert Berenson, Acknowledging the
Elephant: Moving Market Power and Prices to the Center of Health Policy, HEALTH AFF.
BLOG (June 3, 2014), http://healthaffairs.org/blog/2014/06/03/acknowledging-the-elephant-moving
-market-power-and-prices-to-the-center-of-health-policy/ [https://perma.cc/CC5X-4M9R].
19. WHITE ET AL., supra note 18, at 2–4.
20. OFFICE OF ATT’Y GEN. MARTHA COAKLEY, supra note 17, at 2–4; Joseph P. Newhouse
& Alan M. Garber, Geographic Variation in Health Care Spending in the United States:
Insights from an Institute of Medicine Report, 310 JAMA 1227, 1227–28 (2013) (“[P]rice variation is responsible for an estimated 70% of the total geographic variation in spending among
privately insured persons. Variation in wage levels and variation in the quantity of services
delivered are almost equally responsible for the remaining estimated 30% of spending variation.”); Cooper et al., supra note 12, at 3 (concluding that hospital market structure, that is, the
degree of competition in the market, is strongly associated with hospital prices); GINSBURG,
supra note 18, at 7.
21. OFFICE OF ATT’Y GEN. MARTHA COAKLEY, supra note 17, at 3–4; see GINSBURG,
supra note 18, at 6.
22. Katherine Baicker & Helen Levy, Coordination Versus Competition in Health Care
Reform, 369 NEW ENG. J. MED. 789, 789–91 (2013).
23. Accountable Care Organizations (ACO), CTRS. MEDICARE & MEDICAID SERVS. (Jan.
6, 2015, 2:58 PM), https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ACO
/index.html?redirect=/ACO/ [https://perma.cc/2JH4-FX2D].
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Despite all the hoped-for benefits from health care integration, there is no empirical
evidence showing that the wave of integration is generating efficiencies or widespread savings. On the contrary, all the emerging literature on vertical integration
between hospitals and physicians points in the same troubling direction: vertical integration is associated with increased prices and reduced consumer welfare. 24
This article examines the overlooked half of the narrative on health care cost
control: rising prices and the policy levers held by the states to address them.
Specifically, we challenge the conventional wisdom that policies directed at health
care integration and utilization controls alone can meaningfully reduce health
spending, and we consider the potentially harmful effects from increasing vertical
integration between hospitals and provider organizations.25 We argue that unregulated vertical integration is a double-edged sword that poses significant risks to
consumer welfare from increased health care prices. Due to already highly
concentrated health care markets and the limits of federal antitrust enforcement of
vertical health care integration, states have both an opportunity and an obligation to
supplement federal antitrust efforts to control rising health care prices stemming
from health care integration.
The way to address the double-edged sword of vertical health care integration is
to allow beneficial integration with a quid pro quo that the integrating entities must
submit to oversight regarding price, quality, and competition. We offer six policy
initiatives available to states in order of least to greatest amount of intervention into
the state’s health care market: all-payer claims databases (APCDs); state antitrust
enforcement or immunity; ACO certification programs; rate oversight authority; provider price caps; and rate regulation. 26
Given the range of initiatives, legislators should vary their policy prescription
based upon the particular market and political dynamics in the state. Three key ingredients, however, emerge as critical for effective state oversight of vertical integration and private price increases: (1) Information—states must have a means to
collect and analyze price, quality, utilization, and market data, such as an all-payer
claims database, in order to match their policy approach to their market and to evaluate their success; (2) Independence—state oversight bodies must be insulated from

24. A discussion of this literature is set forth infra Part II.
25. In this article, we focus specifically on vertical integration because antitrust authorities have generally treated its use as procompetitive. As a result of this treatment, antitrust
analysis and guidance for vertical integration efforts are much less robust than for horizontal
consolidation among direct substitutes or competitors, such as mergers among hospitals.
26. States may also increase health care competition by implementing policies to eliminate certificate-of-need laws that pose barriers to entry for new health facilities, loosening of
scope-of-practice laws to allow different types of mid-level providers to compete with or augment the supply of physician services, or regulating provider-plan contracting practices to restrict anticompetitive use of most-favored-nation or anti-tiering clauses. We do not discuss
these policies here because they mostly address threats to horizontal competition rather than
describing ways states can oversee vertically integrated entities. For a good discussion of these
options, see NAT’L ACAD. SOC. INS., ADDRESSING PRICING POWER IN HEALTH CARE MARKETS:
PRINCIPLES AND POLICY OPTIONS TO STRENGTHEN AND SHAPE MARKETS 29–37 (2015)
[hereinafter NASI PANEL ON PRICING POWER], https://www.nasi.org/sites/default/files/research
/Addressing_Pricing_Power_in_Health_Care_Markets.pdf [https://perma.cc/7ASE-W8YG].
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the powerful providers they oversee; and (3) Regulatory Authority—state oversight
bodies must have the authority to enforce or impose limits on providers’ prices when
they become too high.
This Article explores the states’ critical role in addressing the double-edged sword
of health care integration. Part I documents the rise of vertical health care integration
driven by its theoretical benefits, as well as the legal incentives to integrate. Part II
describes the emerging evidence that vertical integration in health care may also pose
a threat to competition and lead to increased prices. Part III explains that states have
a key role to play in managing this threat because of the limits of federal antitrust
enforcement, federal oversight, and market-based solutions. Part IV posits that the
way to manage the double-edged sword of vertical health care integration is to permit
beneficial integration to proceed in exchange for price and quality oversight by states.
Part IV goes on to examine an array of policy tools that all build upon robust allpayer claims data gathering to inform future health policy decisions.
I. THE RISE OF HEALTH CARE INTEGRATION
Health care in the United States is notoriously fragmented and inefficient. 27 A
popular policy view posits that increased vertical integration and collaboration in
health care can reduce waste, increase efficiency, and improve quality by altering the
financial incentives to overuse care and permitting physicians and other providers to
more easily coordinate care. 28 Accordingly, recent health care reforms have created
powerful incentives for providers and even health plans to form vertically integrated
systems, whether to operate an ACO or better manage the shift away from fee-forservice to new payment models based on value. 29 But little is known about what
conditions are required for health care integration to achieve these efficiencies or
whether the benefits of integration outweigh the risks to competition and concentration of market power. Part I explores the theoretical promise of vertical health care
integration and the incentives for integration contained in various legal reforms, including the ACA.
A. Theoretical Benefits of Vertical Integration
Unlike horizontal consolidation,30 vertical integration is theoretically ambiguous—it may achieve increased efficiencies, but it may also serve to enhance market

27. See, e.g., THE FRAGMENTATION OF U.S. HEALTH CARE: CAUSES AND SOLUTIONS (Einer
Elhauge ed., 2010).
28. See Cutler, supra note 6, at 1133–34.
29. Similar incentives exist for horizontal consolidations between hospitals or between
health insurers. Indeed, the pace of horizontal mergers in health care has also increased following the passage of the ACA. See Leemore Dafny, Hospital Industry Consolidation—Still
More To Come?, 370 NEW ENG. J. MED. 198, 198 (2014).
30. The literature on the anticompetitive potential of horizontal consolidation among hospitals is clearer than for vertical integration. See, e.g., MARTIN GAYNOR & ROBERT TOWN,
ROBERT WOOD JOHNSON FOUND., THE IMPACT OF HOSPITAL CONSOLIDATION—UPDATE
(2012), http://www.rwjf.org/content/dam/farm/reports/issue_briefs/2012/rwjf73261 [https://
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power.31 In microeconomics, vertical integration refers to the common ownership of
two different stages of production of a product, such as manufacturing and distribution.32 In health care, vertical integration refers to the integration of suppliers of different components of health care services, such as hospitals and physicians, as well
as integration of health systems and health plans, which collectively supply different
elements of the health care product to the ultimate consumer. 33
According to neoclassical economic models, vertical integration enhances efficiency by reducing transaction costs and arm’s-length contracting across separate
organizations.34 In health care, vertical integration has similarly been thought to improve efficiency through improved care coordination and reduction of fragmentation
among providers and payers.35 Common ownership of hospitals and physician inputs
in the health care “supply chain” can align financial incentives between hospitals and
referring physicians, reduce duplicative or unnecessary care, provide centralized administrative services, and reduce transaction costs by allowing joint contracting with
third-party payers.36 Vertical mergers of hospitals and physicians or health plans into
integrated delivery systems may reduce the costs of complex negotiations between
providers and payers. Between hospitals and physicians, arm’s-length contracts are
costly to establish, whether due to health care fraud and abuse laws that limit
hospital-physician contracts or payment systems that separate hospital and physician
payments.37 As a result, vertical integration in health care has the potential to create
significant efficiencies.

perma.cc/JK6R-397T]. Our analysis, therefore, focuses on the “harder case” of vertical health
care integration. See Thomas L. Greaney, Competition Policy After Health Care Reform:
Mending Holes in Antitrust Law’s Protective Net, 40 J. HEALTH POL. POL’Y & L. 897, 897–98
(2015).
31. Martin Gaynor & Robert J. Town, Competition in Health Care Markets, in 2
HANDBOOK OF HEALTH ECONOMICS 499, 620 (Mark V. Pauly, Thomas G. McGuire & Pedro
Pita Barros eds., 2012).
32. See Austin B. Frakt, Steven D. Pizer & Roger Feldman, Plan-Provider Integration,
Premiums, and Quality in the Medicare Advantage Market, 48 HEALTH SERVS. RES. 1996,
1999 (2013).
33. Christopher Afendulis & Daniel Kessler, Vertical Integration and Optimal
Reimbursement Policy 5 (Nat’l Bureau of Econ. Research, Working Paper No. 17316, 2011).
34. Laurence C. Baker, M. Kate Bundorf & Daniel P. Kessler, Vertical Integration:
Hospital Ownership of Physician Practices Is Associated with Higher Prices and Spending,
33 HEALTH AFFAIRS 756, 756–57 (2014); Gaynor & Town, supra note 31, at 619–20.
35. See, e.g., Baker et al., supra note 34, at 756–57; Lawton Robert Burns, Jeff C.
Goldsmith & Aditi Sen, Horizontal and Vertical Integration of Physicians: A Tale of Two
Tails, 15 ADVANCES HEALTH CARE MGMT. 39, 66–70 (2013); Stephen L. Walston, John R.
Kimberly & Lawton R. Burns, Owned Vertical Integration and Health Care: Promise and
Performance, 21 HEALTH CARE MGMT. REV. 83, 84–85 (1996).
36. Afendulis & Kessler, supra note 33, at 5.
37. Baker et al., supra note 34, at 757; William M. Sage, Getting the Product Right: How
Competition Policy Can Improve Health Care Markets, 33 HEALTH AFF. 1076, 1078 (2014).
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B. Policy Incentives for Vertical Integration
Based on these economic assumptions and the utilization-centered narrative of
health care cost containment,38 the ACA offers numerous incentives to promote vertical integration in health care. The primary example is the Medicare Shared Savings
Program, which encourages providers to form ACOs for Medicare beneficiaries, with
the intent that private payers would adopt the model as well. 39 ACOs are groups of
providers organized into a formal legal entity that agrees to be collectively accountable for the cost and quality of the health care for a defined population of individuals.40 The ACO structure rewards groups of providers for improving quality and care
coordination while reducing unnecessary utilization by paying them a share of the
amount they save for the payer.41 To the extent that an ACO assumes insurance risk,
the providers within the ACO have an incentive to reduce the overall volume of services and reduce waste.42 Shared savings payments for ACOs further encourage hospitals and physicians to integrate to increase efficiency and reduce costs. Vertically
integrated entities can more easily share data, eliminate redundancy, invest in
interoperable health information technology, and implement clinical protocols that
cross care settings. Further, vertical integration can make it easier to reduce “internal
agency problems and take advantage of economies of scope.”43
Other Medicare programs, such as bundled payments or value-based purchasing,
also create incentives for fragmented providers to work together, coordinate care,

38. See supra text accompanying notes 4–7. Federal cost control policy also tends to focus
on Medicare, and because the government sets the prices in Medicare, the opportunities to
control Medicare spending focus on ways to reduce overutilization. However, these assumptions do not apply to private health care spending. See Cooper et al., supra note 12, at 1–3
(“[V]ariation in providers’ transaction prices across HRRs [Hospital Referral Regions] is the
primary driver of spending variation for the privately insured, whereas variation in the quantity
of care provided across HRRs is the primary driver of Medicare spending variation.”);
Newhouse & Garber, supra note 20, at 1227–28 (“Whereas price variation explains almost
none of the overall variation in Medicare expenditures (after adjusting for wage variation),
price variation is responsible for an estimated 70% of the total geographic variation in spending among privately insured persons.”).
39. See 42 U.S.C. § 1395jjj (2012); 42 C.F.R. § 425 (2015); see also Thomas L. Greaney,
Regulators as Market-Makers: Accountable Care Organizations and Competition Policy, 46
ARIZ. ST. L.J. 1, 16–17 (2014).
40. Gary E. Bacher, Michael E. Chernew, Daniel P. Kessler & Stephen M. Weiner,
Regulatory Neutrality Is Essential to Establishing a Level Playing Field for Accountable Care
Organizations, 32 HEALTH AFF. 1426, 1426 (2013).
41. See Elliott S. Fisher, Mark B. McClellan, John Bertko, Steven M. Lieberman, Julie J.
Lee, Julie L. Lewis & Jonathan S. Skinner, Fostering Accountable Health Care: Moving
Forward in Medicare, 28 HEALTH AFF. W219, w222 (2009), http://content.healthaffairs.org
/content/28/2/w219.full.pdf [https://perma.cc/N882-U8NK].
42. JEFF GOLDSMITH, LAWTON R. BURNS, ADITI SEN & TREVOR GOLDSMITH, NAT’L ACAD.
SOC. INS., INTEGRATED DELIVERY NETWORKS: IN SEARCH OF BENEFITS AND MARKET EFFECTS
1–2 (2015).
43. Alison Evans Cuellar & Paul J. Gertler, Strategic Integration of Hospitals and
Physicians, 25 J. HEALTH ECON. 1, 4 (2006).

64

I N DIA NA LA W J OU R NA L

[Vol. 92:55

and collectively internalize the costs of disparate aspects of an entire care episode.
The payment bundling program pays providers a single lump-sum payment to cover
all inpatient, physician, outpatient, and post-acute services involved in the episode
of care.44 The ACA also implements significant payment cuts to hospitals according
to measures of quality and value. These payment changes include Medicare rate cuts
for excessive readmissions45 and hospital-acquired conditions,46 and calculating
Medicare bonuses or penalties based on measures of value. 47 The upshot of all these
Medicare payment reforms for providers is that they are assuming more financial risk
and experiencing major changes to their business and revenue models, built on the
old fee-for-service and diagnosis-based reimbursement methods.
Providers may look to consolidation to maximize their ability to assume financial
risk. Bigger systems have more enrollees, and ACOs need to be sufficiently large to
be able to absorb financial risk and make the financial investments needed to achieve
economies of scope necessary to generate cost savings on which ACO payments depend.48 Furthermore, the Federal Trade Commission (FTC) and Department of
Justice (DOJ) have largely focused their antitrust policy guidance and review on
horizontal provider consolidation, further encouraging providers to integrate
vertically.49
In 2015, Congress passed the Medicare Access and CHIP Reauthorization Act
(MACRA), which, among other things, repealed the formula that ties Medicare physician payments to a “sustainable growth rate” (SGR). 50 MACRA adds to the momentum of provider consolidation by shifting more physicians to value-based and

44. 42 U.S.C. § 1395cc-4 (2012); see also CHAPIN WHITE, JAMES D. RESCHOVSKY &
AMELIA M. BOND, NAT’L INST. FOR HEALTH CARE REFORM, RESEARCH BRIEF NO. 14,
INPATIENT HOSPITAL PRICES DRIVE SPENDING VARIATION FOR EPISODES OF CARE FOR
PRIVATELY INSURED PATIENTS 2 (2014).
45. 42 U.S.C. § 300gg-17(a)(1)(B) (2012); see, e.g., Jordan Rau, Half of Nation’s
Hospitals Fail Again To Escape Medicare’s Readmission Penalties, KAISER HEALTH NEWS
(Aug. 3, 2015), http://khn.org/news/half-of-nations-hospitals-fail-again-to-escape-medicares
-readmission-penalties/ [https://perma.cc/4SMD-AST6].
46. 42 U.S.C.A. § 1395ww(p) (West 2015).
47. 42 U.S.C.A. § 1395ww(o).
48. Stephen M. Shortell, Carrie H. Colla, Valerie A. Lewis, Elliot Fisher, Eric Kessel &
Patricia Ramsay, Accountable Care Organizations: The National Landscape, 40 J. HEALTH
POL. POL’Y & L. 645, 659–60 (2015) (estimating that ACOs need approximately 25,000–
50,000 enrollees to make investments needed for success).
49. See Statement of Antitrust Enforcement Policy Regarding Accountable Care
Organizations Participating in the Medicare Shared Savings Program, 76 Fed. Reg. 67,026
(Oct. 28, 2011); U.S. DEP’T OF JUSTICE & FED. COMM’N, STATEMENTS OF ANTITRUST
ENFORCEMENT POLICY IN HEALTH CARE (1996); FED. TRADE COMM’N & U.S. DEP’T OF
JUSTICE, ANTITRUST GUIDELINES FOR COLLABORATIONS AMONG COMPETITORS 3 (2000); U.S.
DEP’T OF JUSTICE & FED. TRADE COMM’N, HORIZONTAL MERGER GUIDELINES (2010); see also
Deborah L. Feinstein, Director, Bureau of Competition, Fed. Trade Comm’n, Address at Fifth
National Accountable Care Organization Summit—Washington DC: Antitrust Enforcement
in Health Care: Proscription, Not Prescription (June 19, 2014).
50. Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), Pub. L. No.
114-10, § 101(a)(1), 129 Stat. 87, 89 (2015).
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alternative payment models. Also known as the “doc fix,” MACRA replaced the
widely unpopular SGR-based formula with a plan to implement Medicare physician
fee bonuses based on participation in alternative payment models, such as ACOs.51
For physicians who do not participate in alternative payment models, MACRA adjusts their fee-for-service rates according to a merit-based incentive program that
takes into account the physician’s quality measures, resource use, and adoption of
electronic health records.52
On top of the incentives already in the ACA, MACRA pushes more physicians to
join ACOs. Even for physicians who stick with fee-for-service, the incentive-based
adjustments to their fees nudge physicians toward integration with larger systems
due to the administrative burden and expense of implementing quality reporting,
electronic health records, and resource use analysis. Together, the payment reforms
of the ACA and MACRA are driving an upsurge of vertical health care integration.
The ACA’s incentives extend beyond payment changes. The regulatory environment also favors clinical and financial integration among hospitals, physicians, and
other types of providers (such as post-acute providers) by providing valuable waivers
for onerous regulatory regimes like the Stark Law, Anti-Kickback Statute, and limited antitrust scrutiny to providers who implement a Medicare ACO or bundled payment pilot program.53 Provider liability under the Stark Law, compounded with the
False Claims Act’s treble damages, create an environment of extreme financial risk
for hospitals, physicians, and other providers who seek to more closely align financial incentives and clinical processes. The greatest regulatory flexibility comes with
forming a Medicare-approved ACO because then the ACO participants, and the payments made between them, are largely exempted from having to comply with the
Stark Law and the Anti-Kickback Statute.54
In addition, the antitrust review process for ACOs only applies to independent
entities collaborating to form an ACO, which may also create an incentive for vertically situated health care entities to merge into a unified delivery system prior to
applying to participate in the Medicare Shared Savings Program, to ease the approval
process. While the prior merger would be subject to FTC oversight and review, the

51. Id. § 101(a)(2).
52. Id. § 101(b); Medicare Merit-Based Incentive Payment System (MIPS) and
Alternative Payment Model (APM) Under the Physician Fee Schedule, 81 Fed. Reg. 77,008
(Nov. 4, 2016) (to be codified at 42 C.F.R. pt. 414) (setting forth CMS’s final rule for physician
payment under MACRA); see, e.g., Frequently Asked Questions on MACRA and Medicare
Payment Reform, AM. ACAD. FAM. PHYSICIANS, http://www.aafp.org/practice-management
/payment/medicare-payment/faq.html [https://perma.cc/8K5Y-ZB9M].
53. See 42 U.S.C. § 1899jjj(f) (2012) (granting Secretary of Health and Human Services
the authority to waive requirements of the Stark Law, Anti-Kickback Statute, and Civil
Monetary Penalties Statute as needed to carry out the Medicare Shared Savings Program);
Medicare Program; Final Waivers in Connection with the Shared Savings Program, 76 Fed.
Reg. 67992, 67999–68001 (Nov. 2, 2011); Statement of Antitrust Enforcement Policy
Regarding Accountable Care Organizations Participating in the Medicare Shared Savings
Program, 76 Fed. Reg. 67026 (Oct. 28, 2011); I.R.S. Notice 2011-20, 2011-16 I.R.B. 652.
54. Medicare Program; Final Waivers in Connection with the Shared Savings Program,
supra note 53, at 67999–68001.
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FTC has challenged very few vertical mergers, and none among health care entities.55
Thus, if a hospital or physician group is contemplating forming a relationship to coordinate care, share referrals, and assume responsibility for the health and spending
of a population of patients, there are strong regulatory incentives to merge or form a
fully integrated ACO rather than adopting looser, contractual forms of alignment.
These regulatory incentives are further enhanced by increases in market power and
leverage that could arise from a merger or integration.
Many of the desired benefits of clinical and financial integration, however, do not
require health care entities to merge or formally integrate. Vertical integration can
occur on several levels. The loosest form of vertical integration, the open contract
form, would be a nonexclusive contractual relationship between a hospital and a
group of physicians, such as the hospital’s medical staff or an independent practice
association (IPA), in which the hospital provides some administrative support for
health plan contracting and may engage in nominal care-coordination activities.56 An
intermediate form of vertical integration, the closed contract form, would involve an
exclusive contractual relationship between the hospital and a select group of physicians, in which the hospital provides higher levels of administrative and management
services (e.g., electronic health records, billing, utilization and quality review, etc.),
private health plan contracting, and care coordination.57 The tightest form of vertical
integration is when the hospital owns the physician practices or directly employs the
physicians.58 ACOs themselves can be organized along a spectrum from loose to
tight integration between hospitals and physician-participants. While entities in these
looser models can still engage in significant clinical and financial integration (such
as shared electronic medical records systems, payment incentives, and quality-ofcare reporting mechanisms), tighter forms of integration may be encouraged by financial and regulatory incentives.
Because of the promise of accountable care and the payment incentives through
reform efforts, the pace of all types of vertical health care integration has increased.
From 2004 to 2011, hospital ownership of physician practices, the tightest form of
hospital-physician integration, increased from 24% to 49%.59 The Government
Accountability Office reports that the number of vertically integrated physicians
nearly doubled from 95,000 to 182,000 between 2007 and 2013. 60 Although not all
ACOs necessarily involve vertical integration of hospitals and physicians, most do.61

55. See Feinstein, supra note 49, at 8; see, e.g., St. Alphonsus Med. Ctr.–Nampa, Inc. v.
St. Luke’s Health Sys., Ltd., 778 F.3d 775, 791 (9th Cir. 2015), aff’g Nos. 1:12-CV-00560BLW, 1:13-CV-00116-BLW, 2014 WL 272339 (D. Idaho Jan. 24, 2014).
56. Baker et al., supra note 34, at 759.
57. Id.
58. Id.
59. Id.; David M. Cutler & Fiona Scott Morton, Hospitals, Market Share, and
Consolidation, 310 JAMA 1964, 1966 (2013).
60. U.S. GOV’T ACCOUNTABILITY OFFICE, MEDICARE: INCREASING HOSPITAL-PHYSICIAN
CONSOLIDATION HIGHLIGHTS NEED FOR PAYMENT REFORM 9 (2015).
61. Stephen M. Shortell, Frances M. Wu, Valerie A. Lewis, Carrie H. Colla & Elliott S.
Fisher, A Taxonomy of Accountable Care Organizations for Policy and Practice, 49 HEALTH
SERVS. RES. 1883, 1889 (2014).
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Following the passage of the ACA, the growth of ACOs has been rapid, with more
than 700 ACOs established nationwide by 2015, about evenly split between
Medicare and commercial ACOs.62 ACOs cover approximately 23.5 million individuals, and only about a third of this total (7.8 million) are Medicare enrollees. 63 It is
projected that a majority of Americans will receive their care from an ACO by 2018.64
Some of the same trends driving health care provider integration are also contributing to an increase in plan-provider integrations. New payment models, like global
payments, require provider organizations to assume more financial risk, which entails being responsible for the cost of care for an entire population of patients. Up to
a point, the larger an organization is, the better it is able to assume population risk
and invest in systems to meet quality targets. However, as it does, the provider network must assume more of the functions and capacity of health insurers. An ACO or
a health system that is part of an ACO will be more likely to meet quality and costsavings goals if it has the capacity to manage clinical, quality, and cost data and to
take on financial risk, and one of the easiest ways for providers to acquire this capacity is to merge with a health plan.65
From the payers’ perspective, health insurers are increasingly regulated under the
ACA even while insurance market dynamics are changing. Many plans are either
shifting more of the insurance/financial risk to providers (through ACOs and alternative payment systems) or leaving insurance risk with self-insured employers.
Health plans are marketing their capacities for financial risk management, data gathering and analysis, and care management to providers via management services contracts or consolidation into common entities. 66 The ACA’s requirements, including
medical-loss ratios,67 limits on underwriting activities,68 guaranteed issue,69 and the
Cadillac Tax on costly employer-sponsored health plans70 are altering the business
models of health plans and putting limits on the amount of profits the plans can earn
from their premium revenue. As a result, health plans are looking for ways to increase
their market share and shift their function to more of an administrative role, such as
processing claims and gathering data on quality and cost. These trends are pushing
more health plans to consider combinations with providers.
Consequently, vertical integration between providers and health plans is rising. In
one report from 2012, approximately 20% of hospital networks offered an integrated

62. Shortell et al., supra note 48, at 646.
63. David Muhlestein, Growth and Dispersion of Accountable Care Organizations in
2015, HEALTH AFF. BLOG (Mar. 31, 2015), http://healthaffairs.org/blog/2015/03/31/growth-and
-dispersion-of-accountable-care-organizations-in-2015-2/ [https://perma.cc/45TD-A42D].
64. Id.
65. See Frakt et al., supra note 32, at 1997.
66. Victor R. Fuchs & Leonard D. Schaeffer, If Accountable Care Organizations Are the
Answer, Who Should Create Them?, 307 JAMA 2261, 2262 (2012).
67. 42 U.S.C. § 1395w-27 (2010).
68. 42 U.S.C. § 300gg-3 (2011).
69. 26 U.S.C. § 35 (2012).
70. 26 U.S.C. § 4980I (2010).

68

I N DIA NA LA W J OU R NA L

[Vol. 92:55

insurance plan, with another 20% contemplating doing so.71 Within the Medicare
Advantage market, in which Medicare beneficiaries receive Medicare services
through private managed care plans, about 17% of Medicare Advantage plans were
integrated with providers in 2013.72 A 2015 poll of fifty-eight chief executive officers
of health care providers and plans found that 88% predicted more plan-provider collaboration in the next three to five years.73 For instance, several hospital systems in
California, other than Kaiser Permanente, 74 have begun offering insurance through
Covered California (California’s health care marketplace under the ACA). 75
Whether between hospitals and physicians or plans and providers, vertical integration in health care is on the rise. Providers are rapidly consolidating before we
have a clear sense of what effect this integration will have on health care markets and
prices. The early evidence is ominous.
II. THE DOUBLE-EDGED SWORD OF VERTICAL HEALTH CARE INTEGRATION
Despite its many anticipated benefits, vertical health care integration presents a
double-edged sword. The effort to promote beneficial integration has opened the
door to health care consolidation across the country. Emerging empirical data reveals
that vertical integration carries significant downside risks to competition and consumer welfare through increases in market power, increases in referrals and reimbursement rates, and reductions in consumer choice. Moreover, these studies have
not found any evidence supporting the assumptions that vertical health care integration generates efficiencies or reduces costs.
A. Increased Market Power
Theoretical models suggest that vertical integration between hospitals and physicians can harm competition by conferring greater market power on the merged entity.
First, if at least one of the parties (either the hospital or physician group) has market
power pre-merger, then a merger of the two can increase the aggregate market power
of the merged entity vis-à-vis health plans.76 In 1999, Ester Gal-Or argued that the

71. Roni C. Rabin, Some Hospital Networks Also Become Insurers, WASH. POST
(Aug. 25, 2012), http://www.washingtonpost.com/business/some-hospital-networks-also
-become-insurers/2012/08/25/53e90a72-eb1d-11e1-b811-09036bcb182b_story.html.
72. See Frakt et al., supra note 32, at 1997.
73. Joseph Conn, Closer Provider-Insurer Ties Bring New Challenges, MODERN
HEALTHCARE (Aug. 15, 2015), http://www.modernhealthcare.com/article/20150815/MAGAZINE
/308159969 [https://perma.cc/74G7-AQSW].
74. Kaiser Permanente is the dominant integrated delivery system in California, which
has offered fully integrated care since the 1940s. Fast Facts About Kaiser Permanente, KAISER
PERMANENTE, http://share.kaiserpermanente.org/article/fast-facts-about-kaiser-permanente
[https://perma.cc/3RTE-XMU3].
75. Kathleen E. Foote & Emilio E. Varanini, A Few Thoughts About ACO Antitrust Issues
from a Local Enforcement Perspective, 40 J. HEALTH POL. POL’Y & L. 887, 890 (2015).
76. Esther Gal-Or, The Profitability of Vertical Mergers Between Hospitals and Physician
Practices, 18 J. HEALTH ECON. 623, 625 (1999); Martin Gaynor, Is Vertical Integration
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profitability of vertical hospital-physician mergers depended on the relative competitiveness between the hospital and physician markets. 77 She reasoned that when the
merging hospital and physician markets share similar levels of competitiveness, the
merged entity can negotiate higher rates due to increased market power. 78 The market
power increase is strongest when both merging entities are in highly concentrated
markets. By contrast, when the relative level of competitiveness differs significantly
between the two markets, vertical mergers between physicians and hospitals may be
unprofitable unless the merger includes a vertical restraint requiring exclusivity between the parties.79
One way vertical integration increases the market share of the merged entity is
through tying hospital and physician services together. Hospitals that acquire physician groups can effectively lock up the referral pool of physicians and bundle hospital
and physician services together when negotiating with payers. 80 This type of tying
increases bargaining power of the merged provider-entity because in order for an
insurer to include one provider in its network, it must also include other tied providers or services, often at elevated rates.81 In highly concentrated health-care and
health-insurance markets with significant barriers to entry, tying and refusal to supply can lead to rival exclusion. 82 In its most extreme form, a vertically integrated
entity will require “all or nothing” dealing, in which an insurer must either include
all affiliated providers in its network or none at all. 83 One way of achieving an “all
or nothing” bargaining position is to enter into exclusive agreements between hospitals and physician groups, where the parties are unable to bargain with health plans
outside of the tied entity.84 “All or nothing” dealing can lead to supracompetitive
reimbursement rates across a wide range of providers in a particular provider
organization.
Another way vertical mergers can increase the merged entities’ market power is
through foreclosure.85 Foreclosure occurs when “actual and potential competitors are
disadvantaged due to restricted access to one of the most favorable providers,”

Anticompetitive? Definitely Maybe (but That’s Not Final), 25 J. HEALTH ECON. 175, 180–81
(2006); Afendulis & Kessler, supra note 33, at 5.
77. Gal-Or, supra note 76, at 625.
78. Id. at 624. This was true even in the absence of exclusivity requirements.
79. Id. at 625.
80. Baker et al., supra note 34, at 757.
81. BARAK D. RICHMAN, AM. ENTER. INST., CONCENTRATION IN HEALTH CARE MARKETS:
CHRONIC PROBLEMS AND BETTER SOLUTIONS 13 (Thomas P. Miller ed., 2012), http://www
.aei.org/wp-content/uploads/2012/06/-concentration-in-health-care-markets-chronic-problems
-and-better-solutions_171350288300.pdf [https://perma.cc/NWJ4-XQBD].
82. Robert F. Leibenluft, Antitrust and Provider Collaborations: Where We’ve Been and
What Should Be Done Now, 40 J. HEALTH POL. POL’Y & L. 847, 850 (2015).
83. NASI PANEL ON PRICING POWER, supra note 26, at 17 (describing “all-or-none” bargaining by large, multihospital systems).
84. See Gal-Or, supra note 76, at 625.
85. Thomas L. Greaney & Douglas Ross, Navigating Through the Fog of Vertical Merger
Law: A Guide to Counselling Hospital-Physician Consolidation Under the Clayton Act, 91
WASH. L. REV. 199 (2016).
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making their costs higher for equivalent services and quality. 86 The merger of a
hospital with a physician group can foreclose rival hospitals from accessing the
services of the integrated physicians, thereby increasing market power. 87 In
particular, competitors may lose patient volume needed to support their facilities
because they cannot access the integrated physicians’ referrals.88
Empirical evidence supporting theoretical hypotheses that vertical health care
mergers can be used to increase market power and prices has begun to emerge. 89 In
an earlier study, Alison Evans Cuellar and Paul Gertler similarly found that tighter
forms of hospital-physician integration in the 1990s showed significantly higher
prices and volume than stand-alone, unintegrated providers, supporting the theory
that such vertical integrations are done to increase market power. 90 But Federico
Ciliberto and David Dranove found that vertical integration during the 1990s did not
affect hospital prices.91 The opposite results in these two contemporaneous studies
were seen as consistent with the theory that vertical integration can be both
efficiency-enhancing and anticompetitive. 92 There are differences between the market conditions of the 1990s and today; one significant difference is that the hospital

86. See Frakt et al., supra note 32, at 2000.
87. Gaynor, supra note 76, at 177.
88. Greaney & Ross, supra note 85, at 221. Although courts have not applied the foreclosure theory to a challenged merger, in the St. Luke’s case involving the merger of St. Luke’s
health system and the Saltzer group of physicians, the private plaintiffs in the case, rival hospital St. Alphonsus and surgery center Treasure Valley Hospital, asserted an argument for
competitive harms based on a foreclosure model. St. Alphonsus Med. Ctr.-Nampa, Inc. v.
St. Luke’s Health Sys., Ltd., 778 F.3d 775, 791 (9th Cir. 2015), aff’g 2014 WL 272339
(D. Idaho Jan. 24, 2014). These private plaintiffs posited that St. Luke’s would gain a
monopoly share of the Nampa, Idaho, market for adult primary care “foreclosing virtually all
competition for the hospital admissions of the physician practices it acquires.” Complaint for
Preliminary and Permanent Injunction and Damages at 2–3, St. Luke’s, 778 F.3d 775 (No. 1:12
Civ. 00560), 2012 WL 5882652. The complaint went on to assert that the merger would harm
the plaintiffs by causing the loss of admissions, referrals, and services performed by Saltzer
physicians. Id. Ultimately, the Ninth Circuit struck down the merger based on horizontal
grounds (the merger of physician groups) and thus did not examine the anticompetitive impact
of the vertical integration due to foreclosure. St. Luke’s, 778 F.3d at 791.
89. See Baker et al., supra note 34; Robert A. Berenson, Paul B. Ginsburg & Nicole
Kemper, Unchecked Provider Clout in California Foreshadows Challenges to Health Reform,
29 Health AFF. 699 (2010); Alison Evans Cuellar & Paul J. Gertler, Strategic Integration of
Hospitals and Physicians, 25 J. HEALTH ECON. 1 (2006); Cory Capps, David Dranove &
Christopher Ody, The Effect of Hospital Acquisitions of Physician Practices on Prices and
Spending (Inst. for Policy Research, Northwestern Univ., Working Paper No. WP-15-02,
2015). But see Federico Ciliberto & David Dranove, The Effect of Physician-Hospital
Affiliations on Hospital Prices in California, 25 J. HEALTH ECON. 29 (2006) (finding no increase in costs due to physician-hospital affiliations in California).
90. See Cuellar & Gertler, supra note 89, at 16–17, 26.
91. See Ciliberto & Dranove, supra note 89, at 37.
92. See Gaynor, supra note 76, at 177.
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market is substantially more concentrated today, which may amplify the anticompetitive effects of vertical integration between hospitals and physicians. 93
Indeed, more recent studies are starting to show that current forms of vertical integration can lead to higher prices. Laurence Baker, M. Kate Bundorf, and David
Kessler examined vertical integration between 2001 and 2007 and found that the
tightest form of vertical integration—hospital ownership of physician practices
—was associated with higher hospital prices, increased spending, and only modestly
reduced utilization in the form of hospital admissions. 94 To evaluate integration’s
effects on physician prices, Cory Capps, David Dranove, and Christopher Ody
looked at vertical mergers between 2007 and 2013 and found that physician prices
increased nearly 14% following integration with hospitals. 95 The price increase was
not due to an increase in physician market power through horizontal mergers between
physicians. Rather, the price increase corresponded to the hospital’s market share
prior to integration—the larger the market share, the greater the price increase
—which could be due to the hospital’s ability to charge facility fees for services
previously provided on an outpatient basis or patients’ willingness to pay a premium
for a plan with both a desired hospital and a preferred physician group. 96
James Robinson and Kelly Miller examined vertically integrated organizations in
California between 2009 and 2012 and found that hospital ownership of physician
organizations led to significantly higher total expenditures per patient compared to
physician-owned organizations.97 The expenditures were 10.3% higher for physician
organizations owned by a local hospital, and 19.8% higher when the physician organization was owned by a multihospital system.98 The larger the market share of the
vertically integrated hospital owner, the greater the expenditures. Notably, the study
showed little or no evidence that vertical consolidation of hospitals and physicians
resulted in increased efficiency. 99
Another study by Hannah Neprash, Michael Chernew, Andrew Hicks, Teresa
Gibson, and Michael McWilliams found that markets with greater increases in
hospital-physician integration between 2008 and 2012 experienced significantly
greater increases in outpatient spending and prices.100 Because commercial price differences were greater than differences in Medicare prices, the authors concluded that
the price increases associated with the hospital-physician integration resulted from
enhanced market power of integrated providers, not just the site-of-service

93. See James C. Robinson & Kelly Miller, Total Expenditures per Patient in HospitalOwned and Physician-Owned Physician Organizations in California, 312 JAMA 1663 (2014).
94. Baker et al., supra note 34, at 760.
95. Capps et al., supra note 89, at 3.
96. Id. at 3, 5–7, 36 (suggesting that only 25% of the price increases result from facility fees).
97. Robinson & Miller, supra note 93, at 1668. In this study, expenditures were measured
as the amounts insurers paid health care providers on a per-patient basis, excluding high-cost
patients (incurring >$100,000 in health care expenses annually). Id. at 1665.
98. Id. at 1668.
99. See id.
100. Hannah T. Neprash, Michael E. Chernew, Andrew L. Hicks, Teresa Gibson &
Michael McWilliams, Association of Financial Integration Between Physicians and Hospitals
with Commercial Health Care Prices, 175 JAMA INTERNAL MED. 1932, 1937 (2015).
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differential allowing higher prices for integrated physicians, discussed below. 101 Like
Robinson and Miller’s, the study by Neprash et al. found that hospital-physician integration was not associated with reduced utilization or improved efficiency from
care coordination.102
Empirical data on the effect of vertical integration between health plans and providers is even more limited than hospital-physician integration. In 2013, Austin
Frakt, Steven Pizer, and Roger Feldman examined the impact of plan-provider integration on health care premiums and quality in the Medicare Advantage market. 103
The study revealed that plan-provider integration was associated with higher monthly
premiums and also higher quality ratings than nonintegrated plans. 104 However, only
30% of the premium increase associated with integration was attributable to improvements in quality.105 Although some of the increased premiums could have been
due to benefit enhancements, the authors did not observe a statistically significant
increase in benefit generosity following integration for several benefits examined. 106
The authors hypothesized that the increase in premiums also could have resulted
from an increase in market power conferred on the plan from the integrated provider
organization.107 While the Frakt et al. study has several limitations related to its
generalizability and conclusions,108 it raises significant concerns regarding the ability
of plans and providers to use vertical integration as a means to increase market power
and leverage, warranting significantly more attention from health services researchers and antitrust enforcers.
Overall, the emerging research on vertical integration has found that hospital ownership of physician organizations correlates with higher hospital prices, physician
prices, prices for outpatient procedures, and per-patient expenditures. Furthermore,
the only study on plan-provider integration also found an association between integration and higher premiums. These studies, and the dearth of any findings illustrating significant efficiencies or cost savings, lend support to the view that vertical integration in health care can be used to increase market power and prices.
B. Increases in Referrals and Reimbursement
Another anticompetitive effect of vertical integration is that acquisition of physician groups by hospitals may increase health spending from greater utilization and
patient volume by allowing the hospital to pay for referrals within the bounds of
health care self-referral laws.109 The federal Anti-Kickback Statute and the Stark Law
both provide greater flexibility for hospitals to compensate employed, as opposed to

101.
102.
103.
104.
105.
106.
107.
108.
109.

Id. For discussion of the site-of-service differential, see infra Part II.B.
Neprash et al., supra note 100, at 1938.
See Frakt et al., supra note 32, at 1996.
Id. at 2008.
Id. at 2008–09.
Id. at 2009.
Id.
Id. at 2009–10.
Afendulis & Kessler, supra note 33, at 6–7; Capps et al., supra note 89, at 1.
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contracted, physicians. For example, hospitals can pay employed physicians productivity bonuses for services personally performed by the physician, which would not
be permitted for nonemployed physicians (i.e., independent contractors).110 Hospitals
also can more readily require their employed physicians to refer patients to the hospital or to other integrated providers than they can require of independent physicians.111 Moreover, when the integrated entities share fixed assets, it is easier for
them to financially benefit from referrals within the integrated entity within the strictures of anti-referral and anti-kickback laws.112 Hospitals, for example, are willing to
acquire primary care physicians even if it is a money-losing proposition for the hospital because it allows the hospital to capture (and thus pay for) the primary-care
physicians’ referrals for hospital services. 113 When explaining why hospital ownership of physician organizations led to higher total expenditures per patient, Robinson
and Miller reasoned that higher expenditures could be driven by increased use of
higher-priced services, but it could also be due to higher volume of services, or both.114
A merger between hospitals and physicians may also allow the merged entity to
charge higher prices for certain outpatient services by exploiting the fact that
hospital-based services are typically reimbursed at higher rates than identical services provided in physician-based locations.115 This pricing practice is called the siteof-service differential and is cited as one of the financial incentives driving hospitalphysician integration.116 The site-of-service differential exists in Medicare

110. The Stark Law exception for bona fide employment relationships provides that entities (including hospitals) may pay employed physicians productivity bonuses for services personally performed by the physician. The exceptions for independently contracted physicians,
including the exceptions for fair market value and personal services arrangements exceptions,
do not permit productivity bonuses. 42 C.F.R. § 411.357(c) (2008) (bona fide employment
relationships); 42 C.F.R. § 411.257(d) (personal services arrangements); 42 C.F.R.
§ 411.357(l) (fair market value compensation). The Anti-Kickback Statute safe harbor for employees permits “any amount paid by an employer to an employee, who has a bona fide employment relationship with the employer, for employment in the furnishing of any item or
service for which payment may be made in whole or in part under Medicare, Medicaid or other
Federal health care programs.” 42 C.F.R. § 1001.952(i).
111. See 42 C.F.R. § 411.354(d)(4) (2008) (setting forth the requirements for conditioning
a physician’s compensation on referring to certain providers). Although hospitals may also
require independent physicians to refer to the hospital in a personal services contract, the scope
of the required referrals is limited to those services covered by the employment or personal
services contract. 69 Fed. Reg. 16054, 16069–70 (Mar. 26, 2004). Because of the limited nature of personal services agreements (e.g., call-coverage agreements, medical director agreements), the scope of services subject to required referrals is thus much broader for employed
physicians than under most personal services agreements.
112. See Afendulis & Kessler, supra note 33, at 17.
113. ANN S. O’MALLEY, AMELIA M. BOND & ROBERT A. BERENSON., CTR. FOR STUDYING
HEALTH SYS. CHANGE, ISSUE BRIEF NO. 136, RISING HOSPITAL EMPLOYMENT OF PHYSICIANS:
BETTER QUALITY, HIGHER COSTS? 2 (2011).
114. Robinson & Miller, supra note 93, at 1664, 1668.
115. O’MALLEY ET AL., supra note 113, at 3; Capps et al., supra note 89, at 6.
116. See Neprash et al., supra note 100, at 1933–34.
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reimbursement policy and is replicated in the commercial market. 117 In Capps,
Dranove, and Ody’s research finding that vertical integration between hospitals and
physicians increased physician prices, they estimate that about a quarter of the 14%
price increase resulted from exploitation of reimbursement methodologies that allow
hospitals to charge facility fees for employed physicians.118 In the study by Neprash
et al., the site-of-service differential explained part of the increase in prices for
outpatient services experienced by those areas experiencing the highest increase in
hospital-physician integration.119
C. Agency Problems and Consumer Choice
Hospital ownership of physician practices may exacerbate agency problems between physicians and patients. Agency problems arise between patients (the principals) and physicians (their agents) when physicians’ medical decisions on behalf of
their patients are influenced by the physicians’ financial incentives and practice
norms that may be at odds with the patients’ interests in obtaining the highest quality
care at the lowest price. 120 In the context of hospital services, the physician both orders and performs the hospital service, thus driving demand not only for the type of
service but also for the particular facility at which the service will be performed.121
Theoretically, it is unclear what effect vertical integration of hospitals and physicians may have on agency problems between physicians and patients. On the one
hand, common ownership could align the financial incentives between hospitals and
physicians, and thus improve care coordination and patient welfare. 122 However,
hospital ownership of physicians could also create financial and other incentives for
the physician to refer to the owner-hospital or to increase the volume or intensity of

117. See MEDICARE PAYMENT ADVISORY COMM’N., REPORT TO THE CONGRESS: MEDICARE
HEALTH CARE DELIVERY SYSTEM. 27 (2013), http://www.medpac.gov/docs/default
-source/reports/jun13_entirereport.pdf?sfvrsn=0 [https://perma.cc/WV78-5KDD] (describing
the site-of-service differential in Medicare payment policy); JAMES D. RESCHOVSKY & CHAPIN
WHITE, NAT’L INST. HEALTH CARE REFORM, RES. BRIEF NO. 16, LOCATION, LOCATION,
LOCATION: HOSPITAL OUTPATIENT PRICES MUCH HIGHER THAN COMMUNITY SETTINGS FOR
IDENTICAL SERVICES 1 (2014), http://nihcr.org/wp-content/uploads/2016/07/Research_Brief
_No._16.pdf [https://perma.cc/HE33-KAYK] (describing the site-of-service differential for
private payers).
118. See Capps et al., supra note 89, at 4.
119. Neprash et al., supra note 100, at 1937 (concluding that the increase in outpatient
prices was driven by both an increase in the integrated entity’s bargaining power and the higher
prices driven by the site-of-service differential).
120. Thomas L. Greaney, Economic Regulation of Physicians: A Behavioral Economics
Perspective, 53 ST. LOUIS U. L.J. 1189, 1199–2000 (2009); Paul A. Pautler & Michael G. Vita,
Hospital Market Structure, Hospital Competition, and Consumer Welfare: What Can the
Evidence Tell Us?, 10 J. CONTEMP. HEALTH L. & POL’Y 117, 120 (1994).
121. See Peter J. Hammer, Antitrust Beyond Competition: Market Failures, Total Welfare,
and the Challenge of Intramarket Second-Best Tradeoffs, 98 MICH. L. REV. 849, 864–65 (2000).
122. Laurence C. Baker, M. Kate Bundorf & Daniel P. Kessler, The Effect of
Hospital/Physician Integration on Hospital Choice 3 (Nat’l Bureau of Econ. Research,
Working Paper No. 21497, 2015).
AND THE
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services ordered, rather than to choose the most cost-effective option for the
patient.123
In a study that examined the impact of hospital-physician integration on the patient’s choice of hospital, Laurence Baker, M. Kate Bundorf, and Daniel Kessler
found empirical evidence that hospital ownership of physicians worsens the agency
problem between physicians and patients.124 They found that “a hospital’s ownership
of an admitting physician dramatically increases the probability that the physician’s
patients will choose the owning hospital. . . . [P]atients are more likely to choose a
high-cost, low-quality hospital when their admitting physician’s practice is owned
by that hospital.”125 Although they were unable to determine whether, on net, the
harms of vertical integration to patient welfare outweigh the potential benefits, the
authors concluded that “hospital/physician integration affects patients’ hospital
choices in a way that is inconsistent with their best interests.”126
Even when providers have the right motives for integrating, when large conglomerates gain market power, they tend to use it to command higher prices. Taken together, the empirical picture of vertical integration in health care suggests some
emerging themes: first, tighter forms of integration (e.g., acquisition versus contractual affiliation) are associated with greater increases in prices; second, the greater the
market share of the hospital entity prior to consolidation, the more likely the merger
will have anticompetitive effects; and third, the harms to consumer welfare go beyond higher prices and include incentives to refer patients to lower-value facilities
or higher-cost settings. In addition, there is a noted absence of empirical data illustrating that vertically integrated health care systems improve quality127 or reliably
generate cost savings through reduced utilization or improved efficiency. 128
Although there may be limits on the generalizability of any one of the studies, it is
notable that all the data point in the same direction: that vertical health care integration is associated with increased prices and higher per patient health care spending.

123. O'MALLEY ET AL., supra note 113, at 3.
124. Baker et al., supra note 122, at 18.
125. Id. at 17.
126. Id. at 18–19.
127. J. Michael McWilliams, Michael E. Chernew, Alan M. Zaslavsky, Pasha Hamed &
Bruce E. Landon, Delivery System Integration and Health Care Spending and Quality for
Medicare Beneficiaries, 173 JAMA 1447, 1451–52 (2013) (“[S]pending was higher and quality of care not better for [Medicare] beneficiaries assigned to larger hospital-based groups than
for those assigned to smaller physician groups, consistent with other studies of physicianhospital consolidation. Although integration between physicians and hospitals theoretically
could support continuity during care transitions, readmission rates were highest for hospitalbased groups.”)
128. Neprash et al., supra note 100, at 1937 (finding that “[c]onsistent with prior research,
physician-hospital integration was not associated with lower utilization, suggesting that this
form of provider consolidation has not led to gains in health care efficiency in recent years
through improved care coordination or management”).
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III. THE CENTRAL ROLE OF STATES
Due to significant inefficiencies in the health care markets and the limits of federal
antitrust enforcement, states have an important role to play to complement and support federal efforts to address the competitive threats of health care integration. When
market power abuses lead to higher prices and reductions in quality and consumer
choice, the primary remedy has been federal antitrust enforcement. But while federal
antitrust enforcement has a key role to play, it cannot be the only weapon in the
arsenal. First, given the rapid rate of collaboration and consolidation in health care,
the Federal Trade Commission and the Department of Justice (the Antitrust
Agencies) simply do not have the resources or capacity to police all of the consolidation efforts under way throughout the country. 129 Second, federal antitrust enforcement offers a powerful means of preventing anticompetitive mergers and collaborations but has proven less successful at balancing the pro- and anticompetitive effects
of a proposed merger or correcting anticompetitive conduct following consolidation.130 At a time when state and federal governments are incentivizing vertical integration, and in which the majority of health care markets in the United States are
already highly concentrated,131 policy makers need more nuanced tools that they can
deploy throughout the country.
States are in a unique position to assist in this effort. First, state governments
oversee most of the regulation of insurance and health care within the state, which
will enable them to design new policies that complement existing regulatory structures. For instance, states could require payers to report all of their claims to a state
all-payer claims database (APCD)132 to promote a better understanding of the drivers
of health care prices and provide federal antitrust agencies with valuable information
on markets throughout the state. Second, state actors may have existing relationships
with market stakeholders and a better understanding of market dynamics in local
health care markets, which can improve policy selection. Third, state attorneys general have broader mandates than federal antitrust enforcement agencies, which enable them to analyze the actions of health care providers and insurer organizations
through a consumer-protection or community-benefits lens, broadening both the
range of harms that are evaluated and potential enforcement tools. Fourth, allowing
states to monitor the impact of vertical integration in a wide variety of market settings

129. See Martin Gaynor, Competition Policy in Health Care Markets: Navigating the
Enforcement and Policy Maze, 33 HEALTH AFF. 1088, 1090 (2014); Greaney, supra note 39,
at 27; Clark C. Havighurst & Barak D. Richman, The Provider Monopoly Problem in Health
Care, 89 OR. L. REV. 847, 871 (2011).
130. See Feinstein, supra note 49, at 15 (“Conduct remedies do not restore the competitive
status quo and raise several concerns.”); see also Greaney, supra note 39, at 12 (“A common
misapprehension among legislators and policymakers is that antitrust law provides a reliable
counterforce to monopoly.”).
131. See Cutler & Scott Morton, supra note 59, at 1966.
132. Note, however, that in Gobeille v. Liberty Mutual Ins. Co., the Supreme Court held
that ERISA preempts state requirements for self-insured employer health plans to report to
APCDs. 136 S. Ct. 936 (2016). For further discussion, see infra notes 152–59 and accompanying text.
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and try different regulatory approaches will speed understanding of whether and under what circumstances the benefits of engaging in vertical integration outweigh the
risks. Finally, states can learn and exchange best practices for developing APCDs
and other regulatory models, easing the transition for states with less experience.133
Enhancing state and federal collaboration will expand both the information and policy tools available to regulators aiming to control health care costs, as well as allow
available resources to be targeted to the most appropriate entities and markets.
Increasing state involvement does create some risks. Most importantly, the existence of relationships between market stakeholders and government officials also
risks agency capture and undue political influence over legislation and regulation.134
Many states have had well-intentioned policy initiatives, such as certificate-of-need
laws and licensure programs, co-opted by political and financial interests.135 In states
with powerful health provider or insurance entities, maintaining the independence of
the APCD and oversight entities will be essential. For example, the Massachusetts
legislature created the Massachusetts Health Policy Commission (HPC) as an independent state agency that resides in, but is not under the control of, the Executive
Office of Administration and Finance. HPC is “not subject to the supervision and
control of any other executive office, department, commission, board, bureau,
agency or political subdivision of the commonwealth.”136 Instead, an eleven-member
Board of Commissioners with guidance from a broadly representative advisory council govern the agency.137 HPC is funded solely by assessments taken from industry
participants rather than from state general revenue. 138 Given the wealth and political
power of many insurance companies and health care systems, state legislatures
should carefully insulate any oversight entities in terms of both governance and
funding.
Further, state regulation without the requisite expertise and resources to engage
in continued oversight and enforcement risks exacerbating existing problems. Recently, several states have offered immunity from state and federal antitrust laws to

133. For instance, much of the legal, technical, and organizational infrastructure necessary
to implement an APCD could be transferrable across states.
134. Regulatory or agency capture refers to “the phenomenon whereby regulated entities
wield their superior organizational capacities to secure favorable agency outcomes at the expense of the diffuse public.” Nicholas Bagley, Agency Hygiene, 89 TEX. L. REV. 1, 2 (2010).
Others have defined agency capture as “the control of agency policy decision making by a
sub-population of individuals or organizations outside the agency.” Susan Webb Yackee,
Reconsidering Agency Capture During Regulatory Policymaking, in PREVENTING
REGULATORY CAPTURE: SPECIAL INTEREST INFLUENCE AND HOW TO LIMIT IT 292, 296 (Daniel
Carpenter & David Moss eds., 2013).
135. See, e.g., Frances H. Miller, Antitrust and Certificate of Need: Health Systems
Agencies, the Planning Act, and Regulatory Capture, 68 GEO. L.J. 873 (1979–1980).
136. See MASS. GEN. LAWS ANN. ch. 6D, § 2(a) (West 2016). For a detailed discussion of
Certificate of Need statutes and regulations in health care, see ROBERT J. CIMASI, THE U.S.
HEALTHCARE CERTIFICATE OF NEED SOURCEBOOK (2005).
137. Ch. 6D, § 2-4
138. See id. § 2 (setting forth the structure of the Massachusetts Health Policy
Commission).
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vertically integrating health care entities, which drew criticism from federal officials
who argued the practice potentially immunizes anticompetitive behavior and results
in consumer harm if the states fail to appropriately oversee and regulate the entities.139 As successful oversight and enforcement measures often require substantial
financial, personnel, and knowledge-based resources, states must carefully assess
which policy options are best suited to their particular circumstances. In addition,
federal and state government officials should collaborate and coordinate their efforts
as much as possible to promote efficient oversight and regulation of health care
integration.
Vertical integration in health care continues to be encouraged by state and federal
government entities as a means to control overutilization and promote quality. To
maintain control over the amount of consolidation in the health care market and guide
entities in how to structure their integrations in ways that promote competition, regulators need improved information on how integration may lead to abuses of market
power, greater guidance on the appropriate balance between pro- and anticompetitive
effects, and more nuanced oversight and regulatory tools. With the limits of federal
antitrust tools to address vertical integration in health care, states are uniquely situated to manage the price and quality effects of the emerging forms of health care
combinations, but they must be cognizant of the political risks, resources, and competencies necessary to take on such a role. As set forth in Part IV, this federalized,
“laboratory of the states” model allows jurisdictions to tailor policies to the specifics
of the state’s own health care markets.
IV. STATE OPTIONS TO ADDRESS THE DOUBLE-EDGED SWORD
Because of the limits of federal antitrust enforcement and of market forces to discipline private health care prices, states have the opportunity to complement and supplement federal efforts to address the potential harm to competition from increased
health care consolidation. The double-edged sword of health care integration requires
states to grapple with ways to balance the potential efficiency benefits while controlling the price effects of consolidation. To do so, states can encourage clinical integration, but with a quid pro quo that the integrating entities must submit to price and
quality oversight.
Part IV explores a range of policy options states can use to further these ends. The
strategies include: (A) all-payer claims databases; (B) antitrust enforcement and immunity; (C) ACO certification; (D) rate-oversight authorities; (E) private rate caps;
and (F) provider rate regulation.
These policy options for state oversight of health care integration are explored in
order of least to most regulatory intervention in the market, which also generally
correlates to political difficulty. Although the best combination of these tools will
depend on the specific market and political dynamics in each particular state, as a
general matter, the more consolidated and concentrated a state’s health care market,
the more the state may have to rely on the stronger regulatory devices to curb rising
health care prices.

139. Edith Ramirez, Antitrust Enforcement in Health Care—Controlling Costs, Improving
Quality, 371 NEW ENG. J. MED. 2245, 2246 (2014).
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While states may pick and choose from this menu of policy options, three key
ingredients emerge for effective state oversight of vertical integration and private
price increases: (1) Information—oversight bodies must have access to detailed and
timely price, quality, and utilization claim data; (2) Independence—state oversight
bodies must be insulated from the powerful providers they oversee; (3) Regulatory
Authority—state oversight bodies must have the authority to enforce or impose limits
on providers’ prices when they become too high.
A. All-Payer Claims Databases
To evaluate the impact of integration on health care costs and quality, states must
first gain access to reliable data about their health care prices, quality of care, and
market dynamics. This information will inform the analysis of the role that market
leverage, as opposed to value, plays in setting negotiated health care prices.
Obtaining negotiated health care prices will not be an easy task. Private health
care prices are notoriously opaque and difficult to ascertain. 140 Different plans pay
the same provider different prices for the same service. Providers’ charges vary
wildly from each other for the same service in the same geographic areas.141 Furthermore, nondisclosure agreements, trade secrets claims, and highly complex billing
mechanisms shroud health care prices in a veil of secrecy. 142 But states can get
around many of these barriers by requiring disclosure of the information to a state
entity.143
About a third of all states currently require disclosure of health care claims to an
all-payer claims database (APCD).144 APCDs are large-scale, state-run databases that

140. Morgan A. Muir, Stephanie A. Alessi & Jaime S. King., Clarifying Costs: Can
Increased Price Transparency Reduce Healthcare Spending?, 4 WM. & MARY POL’Y REV.
319 (2013).
141. See Elliott S. Fisher, David E. Wennberg, Thérèse A. Stukel, Daniel J. Gottlieb, F.L.
Lucas & Étoile L. Pinder, The Implications of Regional Variations in Medicare Spending. Part
1: The Content, Quality, and Accessibility of Care, 138 ANNALS INTERNAL MED. 273, 273
(2003) [hereinafter Regional Variations in Medicare Spending Part 1]; Elliott S. Fisher, David
E. Wennberg, Thérèse A. Stukel, Daniel J. Gottlieb, F.L. Lucas & Étoile L. Pinder, The
Implications of Regional Variations in Medicare Spending. Part 2: Health Outcomes and
Satisfaction with Care, 138 ANNALS INTERNAL MED. 288 (2003) [hereinafter Regional
Variations in Medicare Spending Part 2].
142. Muir et al., supra note 140, at 326.
143. See id. But see Gobeille v. Liberty Mut. Ins. Co., 136 S. Ct. 936 (2016) (finding
Vermont’s APCD reporting requirements for self-insured employers were preempted by
ERISA).
144. Interactive State Report Map, ACPD COUNCIL, https://www.apcdcouncil.org
/state/map [https://perma.cc/P5Z4-S5DT] (showing eighteen states with APCDs). As of
October 15, 2015, the eighteen states that have enacted legislation to establish an APCD are
Arkansas, Colorado, Connecticut, Kansas, Maine, Maryland, Massachusetts, Minnesota, New
Hampshire, New York, Oregon, Rhode Island, Utah, Tennessee, Vermont, Virginia,
Washington, West Virginia. Id. The twenty states that that are seriously considering an APCD
are Alaska, Arizona, Delaware, Florida, Hawaii, Idaho, Illinois, Iowa, Kentucky, Louisiana,
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collect health care claims data and provider data from all payers in the state, including private insurers, Medicaid, the Children’s Health Insurance Program (CHIP),
self-insured employers, dental insurers, prescription drug plans, state employee
health plans, and others. Furthermore, several APCDs pair price and quality data for
providers.145 States generally use APCDs to collect data on patient demographics,
diagnoses, services rendered, charges, payments, and procedure codes.146 According
to the APCD Council, a nonprofit entity that monitors APCD creation, eighteen states
have enacted legislation to create an APCD, with another twenty states demonstrating a strong interest in doing so.147
APCDs are often thought of as tools for promoting consumer price transparency,148 but their functions go far beyond providing pricing information to consumers. For example, by marrying claims data with quality assessments, APCDs can allow policy makers to monitor the impact of vertical integration on price and quality
under various market conditions. Given the experimental nature of ACOs, access to
data is essential to evaluating whether they can achieve their procompetitive goals of
promoting quality improvement and cost-saving efficiency, or whether their potential anticompetitive effects outweigh any consumer benefit. For instance, policy makers will need to know whether vertical integration in their market changes provider
referral patterns in ways that harm quality of care or patient outcomes. With all the
changes set in motion by the ACA, it is essential to be able to learn from experience
and adapt regulations quickly in response to shifting market dynamics. 149
The collection of APCD data both underlies and informs all of the subsequent
policy options discussed below and should be a precursor to the selection of an approach to manage the double-edged sword of health care integration and consolidation. Policy makers could use APCD data to implement policy incentives targeting
consumers, purchasers, providers, and payers. For instance, if a dominant provider
engaged in anticompetitive conduct to drive up prices to supracompetitive levels, the

Michigan, Montana, Nebraska, New Jersey, New Mexico, Ohio, Pennsylvania, South
Carolina, Texas, and Wyoming. Id.
145. The Basics of All-Payer Claims Databases: A Primer for States, THE ROBERT WOOD
JOHNSON FOUNDATION (2014), http://www.rwjf.org/content/dam/farm/reports/issue_briefs
/2014/rwjf409988 [https://perma.cc/7XSU-HJG9].
146. Massachusetts also requires certain provider organizations to register with the state
and submit information on provider costs, charges, and services. The Center for Health
Information and Analysis collects and maintains large databases of provider and payer information that policy makers and researchers can use to analyze market dynamics in the state.
Hospital and Other Provider Data, CENTER FOR HEALTH INFORMATION AND ANALYSIS,
http://www.chiamass.gov/data-index/ [https://perma.cc/JQ9T-7V97].
147. Interactive State Report Map, supra note 144.
148. For examples of consumer facing tools available in Colorado, Maine, and New
Hampshire, see CO MEDICAL PRICE COMPARE, https://www.comedprice.org/#/home
[https://web.archive.org/web/20161014052429/https://www.comedprice.org/#/home]
(CO
Medical Price Compare is limited to information on childbirth, knee replacement, and hip
replacement services); COMPAREMAINE: HEALTH COSTS & QUALITY, http://www
.comparemaine.org/ [https://perma.cc/9GQ8-SG3F]; Health Costs for Consumer, N.H.
HEALTHCOST, http://nhhealthcost.nh.gov/health-costs-consumers [https://perma.cc/5USX-9WA8].
149. See Cutler, How Health Care Reform Must Bend the Cost Curve, supra note 6, at 1131–35.
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state could consider bringing an antitrust enforcement action, implementing some
form of rate regulation, or finding ways to incentivize market entry.
While the creation of an APCD presents numerous opportunities and benefits,
doing so also raises significant challenges. Without question, the creation and
maintenance of any statewide database will require substantial financial support and
resources. However, with APCDs, obtaining a usable, standardized, and complete set
of data from various payers and providers poses the biggest challenge. For example,
all quality, price, and patient data must be converted to standardized metrics and all
patient data must be de-identified. Given the confidential nature of the database, the
state will also need to impose significant data-security measures. States may also
face additional challenges from providers and insurers claiming that the pricing data
constitutes a trade secret or is subject to a nondisclosure agreement.150 State legislatures can address many of these concerns directly by requiring payers and providers
to submit health care claims data in standardized formats to the state APCD and including a provision that exempts APCD reporting requirements from nondisclosure
agreements and trade secrets claims.151
Unfortunately, the Supreme Court recently dealt a significant blow to state
APCDs in Gobeille v. Liberty Mutual Insurance Co.152 The 6-2 opinion held that the
Employee Retirement Income Security Act (ERISA) preempts state APCD reporting
requirements for self-funded employee health plans, depriving states of essential information on health care utilization, pricing, and quality. 153 Nationally, 61% of workers with employer-based health insurance are in self-funded plans, which represents
a significant portion of the population state health policy makers aim to target with
healthcare reforms.154 Moreover, individuals with employer-based health insurance
tend to be healthier than those covered by public payers, so removing claims data for
a majority of individuals with employer-based coverage from the database can skew
the data and undermine the accuracy of any policy analysis performed using the data.155
States seeking to obtain claims data for employees with self-insured employers
have three options after Gobeille.156 First, states could gather and analyze the more
limited set of health care claims data by continuing to require APCD data from all

150. Muir et al., supra note 140, at 326.
151. Such requirements could be imposed via legislation, state agency regulation, or, in the
case of trade secrets, through a judicial opinion.
152. 136 S. Ct. 936 (2016).
153. Id. at 946–47. For a good discussion of the case and what is at stake for APCDs, see
Nicholas Bagley & Christopher Koller, Transparency and the Supreme Court—Can
Employers Refuse To Disclose How Much They Pay for Health Care?, 373 NEW ENG. J.
MED. 1 (2015).
154. THE KAISER FAMILY FOUND. & HEALTH RESEARCH & EDUC. TRUST, EMPLOYER
HEALTH BENEFITS ANNUAL SURVEY 2016, § 10 (2016).
155. Amicus Brief to the Second Circuit on Behalf of Harvard Law School Center for
Health Law & Policy at 20, Gobeille, 136 S. Ct. 936 (No. 14-181).
156. Erin Fuse Brown and Jaime King, The Consequences of Gobeille v. Liberty Mutual
Ins. Co. for Health Care Cost Containment, HEALTH AFF. BLOG (Mar. 10 2016),
http://healthaffairs.org/blog/2016/03/10/the-consequences-of-gobeille-v-liberty-mutual-for-health
-care-cost-control/ [https://perma.cc/B7P7-HMUB].
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other types of payers, including fully insured employee-benefit plans, public payers,
and individual and small-group plans within and outside the exchanges, and by encouraging self-insured employee health plans to submit information on a voluntary
basis.157 Second, despite being less efficient and more expensive than obtaining the
data from payers, states could require health care providers to submit the missing
data from self-insured employees.158 Finally, states could request that the federal
government, via the Departments of Labor and Health and Human Services, mandate
collection of relevant claims data from ERISA plans. 159 A federal requirement could
standardize data for inclusion in all state APCDs, which could facilitate data analysis
and comparison between states.
A final challenge is that creation of an APCD requires significant thought regarding the amount and scope of data disclosure. Several antitrust enforcers and academics have expressed concerns that, depending on the market dynamics, widespread
disclosure of all health care price and quality data could lead to increased prices or
collusion.160 Determining which data to disclose, to whom, and in which market, will
require substantial analysis and oversight, which again requires resources.
Despite these numerous challenges, states need comprehensive health care price,
utilization, and quality data to inform their health care cost-containment policies.
Thus, states must strive to collect and access this data notwithstanding these challenges. Information forms the basis of any effective state action to address to the
competitive risks of health care integration and consolidation.
B. Antitrust Enforcement and Immunity
Having reliable data will greatly facilitate state decision making on when to incentivize or curtail health care integration. States can manipulate the use of state and
federal antitrust laws to either vigorously challenge anticompetitive conduct or immunize certain actors from prosecution under the laws via the state action doctrine.
A state with highly concentrated health care markets can actively enforce state and
federal antitrust laws to prevent proposed integration from harming competition.

157. Voluntary data submission has some precedent. Virginia has implemented an entirely
voluntary APCD, and four other states use voluntary data collection into databases similar to
APCDs. See VA. CODE ANN. § 32.1-276.7:1 (Supp. 2016); see also APCD Council, supra note
144.
158. See Nicholas Bagley, The Supreme Court’s Wrongheaded Decision in Gobeille,
INCIDENTAL ECONOMIST (Mar. 3, 2016, 11:50 AM), http://theincidentaleconomist.com/wordpress
/the-supreme-courts-wrongheaded-decision-in-gobeille/ [https://perma.cc/Q87P-5G4X].
159. The majority in Gobeille, and Justice Breyer in his concurrence, suggested federally
mandated data collection as solution to replace the lost APCD data from ERISA self-funded
plans. Gobeille, 136 S. Ct. 936, 949–50 (2016) (Breyer, J., concurring). For an example of a
state-based proposal for a federal requirement for the submission of health care claims data by
ERISA plans, see National Academy for State Health Policy, Comment on Department of
Labor Notice of Proposed Rulemaking (Sept. 20, 2016), https://www.regulations.gov
/contentStreamer?documentId=EBSA-2016-0010-0033&attachmentNumber=1&disposition
=attachment&contentType=pdf [https://perma.cc/VF3U-HL5X].
160. See, e.g., Foote & Varanini, supra note 75, at 891; Muir et al., supra note 140, at 354.
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Alternatively, states can encourage integration by granting state action immunity
from state and federal antitrust laws to integrated health care entities via legislation
or Certificates of Public Advantage (COPAs).161 Regardless of a state’s chosen path,
vigorous oversight and significant data monitoring will be essential to controlling
costs and preserving quality in the face of increased concentration.
1. Antitrust Enforcement
States can challenge anticompetitive conduct by enforcement of the federal or its
own state antitrust laws. At the federal level, the Sherman Act and the Clayton Act
prohibit anticompetitive mergers, collaborations, and conduct. 162 In addition, fortynine states have their own antitrust laws that promote and protect competition. 163
Given the market-specific information required to bring an antitrust enforcement
challenge, state officials are well positioned to identify integration proposals that
threaten to harm competition. State attorneys general can challenge mergers and collaborations and bring enforcement actions both independently and in conjunction
with a federal action. Joining with the federal antitrust agencies to bring an action
can be an especially effective means for states to leverage both the expertise and
resources of the federal agencies as well as their own knowledge of existing market
dynamics.164
State attorneys general, like the federal antitrust agencies, generally have the opportunity to review a proposed integration, which could be a formal merger or a
looser collaboration, both at the time of its creation and on an ongoing basis. While
the antitrust analysis typically differs between horizontal mergers, vertical mergers,
and collaborations, the FTC generally considers similar factors when addressing
health care provider integrations.165 At the time of a proposed integration, antitrust
enforcers initially consider whether a proposed merger or collaboration is per se illegal.166 Initial concerns for enforcers include (1) whether the integration could create
potential efficiencies such as cost savings, quality improvement, and transactional
efficiencies; (2) whether the proposed integration is a legitimate attempt to achieve
those efficiencies or a means to enhance market power; and (3) whether the

161. See ROBERT A. BERENSON & RANDALL R. BOVBJERG, URBAN INST., CERTIFICATES OF
PUBLIC ADVANTAGE: CAN THEY ADDRESS PROVIDER MARKET POWER? 4 (2015), http://www
.urban.org/research/publication/certificates-public-advantage [https://perma.cc/V68Q-J7RM].
162. 15 U.S.C. §§ 1–7, 12–18 (2012).
163. Pennsylvania, which is the only state without a separate antitrust law, enforces competition under its Unfair and Deceptive Practices statute. 73 PA. STAT. AND CONS. STAT. ANN.
§ 201-1 (West Supp. 2016).
164. See, e.g., Saint Alphonsus Med. Ctr.-Nampa Inc. v. St. Luke’s Health Sys., Ltd., 778
F.3d 775, 791 (9th Cir. 2015).
165. See Feinstein, supra note 49, at 3–5 (explaining the FTC’s approach to enforcement
in health care markets); Statement of Antitrust Enforcement Policy Regarding Accountable
Care Organizations Participating the Medicare Shared Savings Program, supra note 49; FTC
ET AL., HORIZONTAL MERGER GUIDELINES, supra note 49; FTC ET AL., ANTITRUST GUIDELINES
FOR COLLABORATIONS AMONG COMPETITORS, supra note 49, at 3.
166. See Feinstein, supra note 49, at 4.
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efficiency goals could be obtained through a means that poses less of a threat to
competition.167 For an existing entity, enforcers consider whether the current conduct
of the entity is on balance harming competition. If on initial review the state finds
that its antitrust concerns are not satisfied, it can engage in further investigation.
Given the potential benefits of vertical integration in health care, the majority of
proposed integrations should survive initial review and not be challenged as per se
illegal. Once a bona fide integration is established, antitrust enforcers will review the
integration under a “rule of reason” standard.168 As the Director of the FTC’s Bureau
of Competition Deborah Feinstein pointed out at the Fifth National Accountable Care
Organization Summit in June 2014, “the rule of reason analysis applied to provider
collaborations generally follows the same framework contained in the Horizontal
Merger Guidelines.”169 The rule of reason analysis compares the state of competition
with and without the proposed integration and requires the parties to define the relevant product and geographic markets, identify the market participants, calculate market shares and concentration, consider the likelihood of market expansion, and determine whether any efficiencies are likely to result.170 Antitrust enforcers will
further examine whether the proposed integration will likely harm competition by
increasing “the ability or incentive profitably to raise price above or reduce output,
quality, service, or innovation below what likely would prevail” in its absence. 171
Rule of reason analysis is flexible and market specific in its inquiry, and no one factor
is dispositive.172
The most challenging question facing antitrust enforcers in the case of vertical
integration is whether the purported procompetitive effects of the integration will
outweigh any anticompetitive effects. Before antitrust enforcers will credit any procompetitive efficiencies, the health care entities must demonstrate that the claimed
efficiencies are sufficiently cognizable, explicit, and require the proposed level of
integration (merger, joint venture, or affiliation) to produce the procompetitive effects.173 Doing so has proven extremely difficult. 174 For instance, the Ninth Circuit

167. See Ramirez, supra note 139, at 2246. Although, alliances and other collaborations
have not yet been challenged on antitrust grounds; the FTC has expressed concerns that such
collaborations could also harm competition. See also Feinstein, supra note 49.
168. See FTC ET AL., HORIZONTAL MERGER GUIDELINES, supra note 49, at 15–17; see also
FTC ET AL., ANTITRUST GUIDELINES FOR COLLABORATIONS AMONG COMPETITORS, supra note
49, at 3–6.
169. Feinstein, supra note 49, at 4.
170. Id.; see also FTC ET AL., HORIZONTAL MERGER GUIDELINES, supra note 49, at 15–19;
FTC ET AL., ANTITRUST GUIDELINES FOR COLLABORATIONS AMONG COMPETITORS, supra note
49, at 17–21.
171. FTC, ANTITRUST GUIDELINES FOR COLLABORATIONS AMONG COMPETITORS, supra
note 49, at 4.
172. See id. at 4.
173. See Feinstein, supra note 49, at 9 (stating that the claimed efficiencies must be merger
specific, explicit, and cognizable).
174. See Tasneem Chipty & Asta Sendonaris, Economists’ Perspective on the Efficiency
Defense in Provider Consolidations: What Works, What Doesn’t Work, and What We Still
Don’t Know, 19 AHLA CONNECTIONS 16, 17 (2015) (stating “no provider has convinced an
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Court of Appeals found in Saint Alphonsus Medical Center-Nampa, Inc. v. St. Luke’s
Health System that the quality benefits obtained from sharing electronic medical records, standardizing treatment protocols, and integrating physicians across practices
did not require a formal merger; that is, they were not “merger specific.”175 Although
the Ninth Circuit decided St. Luke’s based purely on the anticompetitive potential of
the proposed horizontal merger of primary care physician practices in Nampa, Idaho,
the principle that a merger was not necessary to achieve the purported efficiencies
would also apply in the analysis of a vertical merger.
The complexity of vertical health care integrations will significantly complicate
antitrust analysis.176 Vertical integrations can harm competition in upstream and
downstream markets, as well as in entirely different markets. 177 For example, Health
First, an integrated delivery system in Brevard, Florida, owns and operates health
plans, hospitals, physician groups, urgent care centers, outpatient centers, rehabilitation facilities, diagnostic and treatment centers, and a network of fitness and wellness
services.178 In these cases, it will not be sufficient to analyze only the impact of the
integration in each market in isolation, but instead antitrust enforcers and courts
should analyze the more global impact of the integration on the particular health care
market. This makes conducting the competitive effects analysis significantly more
complex.179 Further, state enforcers may have to consider how to balance procompetitive effects in one market, such as primary care, with anticompetitive effects
in an altogether different market, such as surgical procedures, or whether quality improvements for certain services outweigh across the board price increases. 180 All of
this will require extensive amounts of time, resources, data, and analysis to accomplish in any meaningful way.
However, once a state has decided that a proposed or existing integration is anticompetitive, it must decide upon a remedy. The goal of any antitrust enforcement
action is to restore the opportunity for the market to function without the illegal restraints on competition.181 Antitrust enforcers generally have two kinds of equitable
remedies to choose from: structural and conduct remedies. Depending on the timing

antitrust enforcer that the claimed efficiencies are cognizable and sufficient to offset” the potential harms to competition).
175. 778 F.3d 775, 791 (9th Cir. 2015).
176. See STEVEN C. SALOP & DANIEL P. CULLEY, POTENTIAL COMPETITIVE EFFECTS OF
VERTICAL MERGERS: A HOW-TO GUIDE FOR PRACTITIONERS 5–6 (2014).
177. Id.
178. See Lisa Schenker, Competitor Sues Florida System Health First, MODERN
HEALTH CARE (Sept. 2, 2015), http://www.modernhealthcare.com/article/20150902/NEWS
/150909986?utm_source=modernhealthcare&utm_medium=email&utm_content=externalURL
&utm_campaign=am [https://perma.cc/5XUK-TB8L].
179. See SALOP & CULLEY, supra note 176, at 6.
180. While historically the courts have not permitted benefits in one market to excuse
harms in another, the Horizontal Merger Guidelines do provide some indication that the
Antitrust Agencies may balance cross-market effects when deciding whether to prosecute a
merger. See, e.g., Philadelphia Nat’l Bank v. United States, 374 U.S. 321, 370 (1963); FTC ET
AL., HORIZONTAL MERGER GUIDELINES, supra note 49, at 30 n.14.
181. See Feinstein, supra note 49, at 14.
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of the action and the market conditions, states can use structural and conduct remedies alone or in combination to address anticompetitive concerns arising from greater
consolidation in health care.
a. Structural Remedies
Antitrust enforcers use structural remedies to prevent a proposed merger, to undo
a recent merger, or to require divestiture or other structural change in order to restore
competition.182 In the instance that a vertically integrated entity has not yet or only
recently formed, structural remedies offer a relatively straightforward means of restoring competition by dissolving the integration. Given the level of concentration in
both the health care insurance and provider markets, antitrust enforcers have expressed a strong preference for structural remedies, 183 as preventing anticompetitive
harms prior to consolidation has proven more successful than attempting to address
them after the entities have fully integrated. 184
While structural remedies are frequently used to prevent horizontal mergers, their
use in vertical mergers has rarely occurred because antitrust enforcers generally view
vertical integration as procompetitive. 185 However, given the evidence that vertical
health care integration can increase provider market leverage and prices, antitrust
enforcers should consider structural remedies, both when evaluating proposed vertical integrations and when an existing consolidated entity continues to amass or abuse
its market power.186
In the case of proposed vertical integrations, antitrust enforcers should consider
structural remedies in three instances. First, they should be especially wary of proposed integrations that appear overinclusive in the number of hospitals and/or physicians participating in the integration, as this may signal an attempt to gain market
power in ways that are unnecessary to the efficiency goals of vertical integration. 187
Second, in instances where the integration would involve a significant number of
providers in a particular area, questions arise regarding whether those providers are
eligible to see patients independently from the entity or subject to exclusivity requirements and whether the integration will substantially limit consumer choice. Third,
vertical integrations that consolidate market power across several different provider
markets can create significant leverage in negotiating reimbursements, such that the

182. Id. at 14–16.
183. Id. at 14.
184. See Stephen Tenn, The Price Effects of Hospital Mergers: A Case Study of the SutterSummit Transaction 23 (Fed. Trade Comm’n, Working Paper No. 293, 2008).
185. Edith Ramirez, Comm’r, Fed. Trade. Comm’n, Presentation to Am. Bar Ass’n at the
Antitrust Fall Forum: FTC Behavioral Remedies (Nov. 17, 2011), http://www.americanbar.org
/content/dam/aba/publications/antitrust_law/at311550_fall_forum_panel_5.authcheckdam.pdf
[https://perma.cc/D5VF-CNXL].
186. See, e.g., ANN HOLLINGSHEAD, JAIME KING, BRENT D. FULTON, JOSHUA RUSHAKOFF,
& RICHARD M. SCHEFFLER, STATE ACTIONS TO PROMOTE AND RESTRAIN COMMERCIAL
ACCOUNTABLE CARE ORGANIZATIONS 17 (2015).
187. Statement of Antitrust Enforcement Policy Regarding Accountable Care
Organizations Participating the Medicare Shared Savings Program, supra note 49.
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entity becomes a “must have” and threatens the ability of other organizations to compete.188
Despite the oft-repeated reminder that mergers, once consummated, are difficult,
if not impossible, to unwind, the highly concentrated nature of U.S. health care markets suggests antitrust enforcers should seriously consider using structural remedies
to break down some of the market leverage some providers have amassed over the
last several decades.189 Over the last several decades, health care entities have come
to rely on the fact that mergers, once consummated, will not be undone. As a result,
health care entities have strong incentives to consolidate, even in the face of increased monitoring or limitations via conduct remedies, because the limitations are
only temporary, but the gain in market power is permanent. In many markets, health
care provider organizations have systematically accumulated market power and
abused it in ways that have significantly increased costs and eliminated competitors.
Such abuses of power could result in anticompetitive conduct claims under Section
1 of the Sherman Act or monopolization and attempted monopolization claims under
Section 2 of the Sherman Act. 190 Antitrust enforcers have the authority to break this
market power down in two ways: division of a larger entity into several smaller entities191 or required divestitures in certain geographic regions. 192 The most prominent
example of division of an existing entity into smaller ones occurred in 1983 when
the Department of Justice successfully litigated its case against AT&T, resulting in
the divestiture of several “Baby Bells.”193 Assistant Attorney General William Baxter
created the “Bell Doctrine” to prevent local telephone service providers from leveraging their legally acquired monopolies in local markets to monopolize the national
long distance market.194 While the Bell Doctrine was designed for regulated

188. For a more theoretical description of how amassing market power across a range of
markets will increase leverage in negotiations with a single purchaser, see generally Gregory
S. Vistnes & Yianis Sarafidis, Cross-Market Hospital Mergers: A Holistic Approach, 79
ANTITRUST L.J. 253 (2013); Thibaud Vergé, Portfolio Effects and Merger Control: Full-Line
Forcing as an Entry-Deterrence Strategy (Ctr. Mkt. Pub. Org., CMPO Working Paper Series
No. 02/046, 2003).
189. Antitrust enforcers have rarely won monopolization or attempted monopolization
claims under the Sherman Act; a major victory of this kind could substantially quell anticompetitive behavior for some time.
190. Sherman Act, 15 U.S.C. §§ 1–2 (2012).
191. See generally, Paul L. Joskow & Roger G. Noll, The Bell Doctrine: Applications in
Telecommunications, Electricity, and Other Network Industries, 51 STAN. L. REV. 1249 (1999).
192. See Press Release, FTC Requires Community Health Systems, Inc. To Divest Two
Hospitals as a Condition of Acquiring Rival Hospital Operator, FED. TRADE COMM’N, (Jan.
22, 2014), https://www.ftc.gov/news-events/press-releases/2014/01/ftc-requires-community
-health-systems-inc-divest-two-hospitals [https://perma.cc/DPN5-XG8N]; Virgil Dickson,
Community Health Systems to Spin Off 38 Hospitals, Shift Focus to Larger Markets, MODERN
HEALTHCARE (Aug. 3, 2015), http://www.modernhealthcare.com/article/20150803/NEWS
/150809993 [https://perma.cc/QV6Q-4PU4].
193. United States v. Western Electric Co., 569 F. Supp. 990 (D.D.C. 1983) (modifying
the final judgment in that case, and terminating United States v. AT&T).
194. William F. Baxter, Conditions Creating Antitrust Concerns, with Vertical Integration
by Regulated Industries—“For Whom the Bell Doctrine Tolls,” 52 ANTITRUST L.J. 243, 243–
47 (1983).
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monopolies, many of its principles can be analogized to dominant health care
organizations.195 A successful state or federal antitrust challenge resulting in
divestitures, or other structural remedies dividing the entity into smaller parts, would
serve as a strong deterrent to other entities.
In sum, state antitrust enforcers should use structural remedies to prevent potentially anticompetitive collaborations and mergers from existing, and to break up those
integrated entities that systematically amass and abuse market power.
b. Conduct Remedies
The majority of vertical integrations, however, are unlikely to require structural
remedies, as they will present substantial procompetitive effects that are not so
clearly outweighed by potential harm to competition. In these instances, conduct
remedies are more frequently used to curb anticompetitive behaviors. State and federal antitrust enforcers have typically used conduct remedies to address anticompetitive concerns arising from vertical mergers and joint ventures; the agencies
believed that conduct remedies would enable an entity to gain the procompetitive
benefits of the vertical integration while still restricting any potential anticompetitive
conduct.196
Conduct remedies can be used in two ways to regulate the anticompetitive harms
that may arise from vertical integration. First, conduct remedies provide a means to
limit anticompetitive behavior in a health care entity that has obtained a significant
amount of market power without requiring it to divest portions of its business in ways
that may compromise patient care.197 Second, for entities that are integrating to create
an ACO or other form of integrated delivery system, conduct remedies offer a tool
to protect competition in ways that are tailored to the concerns of a particular market,
while still enabling providers the opportunity to achieve the desired procompetitive
effects of clinical integration.

195. A full explication of how this theory could apply to health care entities is beyond this
scope of this paper, but we feel that antitrust enforcers should begin to consider whether a
structural remedy could be useful in particular instances.
196. DEP’T OF JUSTICE, ANTITRUST DIV., POLICY GUIDE TO MERGER REMEDIES 12–13
(2011). Some common behavioral remedies in vertical mergers include firewalls, nondiscrimination and fair dealing restrictions. See Ramirez, supra note 185.
197. See Opinion of the Comm’n on Remedy, In re Evanston Northwestern Healthcare
Corp., No. 9315 (Apr. 28, 2008), https://www.ftc.gov/sites/default/files/documents/cases
/2008/04/080428commopiniononremedy.pdf [https://perma.cc/4UD6-N4A9]. Instead of
requiring divestiture, the FTC allowed the merged hospitals to establish separate contracting
teams to negotiate with health plans and gave health plans the option to negotiate with the
hospitals separately or jointly. At the time, the FTC’s reasoning behind this conduct remedy
was the “unique circumstances of the case,” including that the hospitals had consummated
their merger seven years earlier, significant integration had already occurred, and that
divestiture could risk patient safety at Highland Park. See Opinion of the Comm’n at 89–91,
In re Evanston Northwestern Healthcare Corp., No. 9315 (Aug. 6, 2007), https://www.ftc.gov
/sites/default/files/documents/cases/2007/08/070806opinion.pdf [https://perma.cc/4ACG-ZEFF].
To qualify this, however, the FTC has since rejected these sort of conduct remedies and now
uses structural remedies.
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The use of vertical integration and ACOs to control costs and improve quality in
health care is still largely experimental. Like any experiment, the model will require
iterative refinement and oversight to improve its results. Conduct remedies permit
this iterative process to continue to maximize the benefits of integration, while minimizing the harm to competition. For example, depending on the concerns in a particular market, antitrust enforcers could impose direct price caps, limits on total health
care expenditures, limits on contract provisions,198 requirements to preserve existing
services, prohibitions on employment restrictions, and limits on further acquisitions
on health care providers.
But using conduct remedies effectively is challenging. Historically, the antitrust
agencies have not favored the use of conduct remedies to control the anticompetitive
effects of proposed horizontal mergers or collaborations.199 Their logic is relevant to
vertical integration as well. First, unlike structural remedies, conduct remedies do
not restore the status quo with respect to competition. 200 Instead, they provide restrictions and oversight over the newly integrated entity, which are often inferior
substitutes for competition between independent providers.201 For instance, direct
price caps have been used to control cost increases following a merger, but it is not
clear if the price caps are higher than what a competitive market would permit. 202
Further, conduct remedies often focus on price, but they are unable to take account
of other impacts of competition like quality improvement and innovation. 203 Second,
conduct remedies are often difficult to enforce and have high administrative costs. 204
Enforcing conduct remedies requires the enforcement agency to either oversee enforcement itself or hire a third party to monitor the entity, both of which require
substantial resources. In some instances, enforcement can be so expensive and burdensome that the remedy can be self-defeating. Finally, conduct remedies are generally time-limited, which begs the question of what happens when the consent decree
ends. Health care entities may find it financially rewarding to consolidate and accept
the conduct remedies and oversight in the short term to obtain greater market leverage in the future.
In comparison to their federal counterparts, state attorneys general may be better
positioned and more willing to use conduct remedies. State officials will be more
familiar with local stakeholders and market dynamics, and they may be more willing
to engage in conduct oversight than to litigate a merger challenge. For instance, the
Pennsylvania Attorney General has successfully negotiated three consent decrees
since 2011 with Geisinger Health System. 205 The most recent decree, involving

198. For example, prohibiting anti-tiering/anti-steering provisions, most favored nation
clauses, all-or-nothing provisions, and exclusive contracting requirements.
199. See Feinstein, supra note 49, at 14–15.
200. Id. at 15.
201. See id.
202. See id.
203. See id.
204. See id.
205. Ober Kaler, Recent State Attorney General Merger Enforcement: Charting a Different
Path from the Feds – or Not?, LEXOLOGY (Oct. 29, 2014), http://www.lexology.com/library
/detail.aspx?g=a2b2048f-475b-468f-9224-96d6e5dcef32 [https://perma.cc/NFG9-W76A].
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Geisinger’s acquisition of Lewiston Health Care Foundation, required caps on price
increases and prohibited most-favored-nation and anti-tiering provisions.206
In Massachusetts, the then-Attorney General, Martha Coakley, negotiated an extensive consent decree with Partners Healthcare conditioning its acquisition of South
Shore Hospital and two Hallmark hospitals on several factors including (1) caps on
price increases and total health care expenditures; (2) component contracting, which
permits health plans to contract with all or some of Partners’s four major components; (3) limitations on Partners’s ability to contract with payers on behalf of affiliated providers; (4) preservation of existing services; and (5) Attorney General approval for any further acquisitions. 207 The Partners consent decree was ultimately
rejected after substantial opposition from the Massachusetts Health Policy
Commission (HPC),208 which estimated that the merger would result in approximately forty million dollars in increased health care expenditures per year and
Partners having more discharges than the next four largest competitors in the state
combined.209 HPC’s impact on the outcome of the Partners merger demonstrates the
importance of states having readily available access to price, quality, and utilization
data for analysis. If the financial impact of the proposed Partners acquisition had not
been so significant, HPC would have been well-suited to oversee the merger and the
conditions of the consent decree. Few states have an agency that has the data, analytical tools, authority, and resources that HPC does to monitor an actor’s health care
system and its costs. Although it has only been in existence for three years, HPC has
already played a large role in shaping the future of health care in Massachusetts, and
its role in antitrust enforcement will continue to develop. Other states interested in
regulating health care costs should follow HPC’s lead, using its progress and setbacks as guidance for policy design.
Overall, antitrust enforcement is an essential tool for states to curb increases in
health care costs driven by abuses of provider and payer market power. But it can be
too blunt or unwieldy an instrument to strike the delicate balance needed to promote
beneficial integration in health care while preventing providers and payers from acquiring too much market power. In some instances, legislation may be preferable to

206. Pennsylvania v. Geisinger Health Sys. Found., No. 1:13-CV-02647-YK (M.D. Pa.
Oct. 28, 2013).
207. Memorandum of the Commonwealth of Mass. in Support of Entry of Final Judgment,
Commonwealth v. Partners Healthcare Sys., Inc., No. SUCV2014-2033BLS (Mass. Super. Ct.
June 24, 2014), http://www.mass.gov/ago/docs/press/2014/memo-in-support.pdf [https://perma.cc
/4G64-37U5].
208. The Massachusetts Health Policy Commission (HPC) is an independent state agency
created to monitor health care costs; develop policies to reduce overall health care costs and
maintain quality; and provide objective, data-driven analyses of specific provider transactions.
See MASS. GEN. LAWS ANN. ch. 6D, § 2 (West 2016). For further discussion of the
Massachusetts HPC, see infra Parts IV.C–IV.D.
209. Memorandum of Decision and Order on Joint Motion for Entry of Amended Final
Judgment by Consent at 27, Commonwealth v. Partners Healthcare Sys., Inc., No. SUCV201402033-BLS2 (Mass. Super. Ct. Jan. 29, 2015), http://www.mass.gov/ago/docs/press/2015
/partners-memo-of-decision-and-order.pdf [https://perma.cc/HT86-849H] (estimating that
total medical spending would increase by more than $38.5 million to $49 million per year).
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conduct remedies for behavior that states wish to curb across all actors, like all-ornothing provisions or most-favored-nation clauses. If enforcers fear eliminating procompetitive efficiencies, they may opt to delay enforcement in ways that can cause
lasting harm to competition. Likewise, if used too aggressively, the threat of antitrust
enforcement could chill integration efforts.
2. State Action Immunity and Certificates of Public Advantage
In some instances, state and federal governments may wish to alleviate that
chilling effect of antitrust law by signaling to health care entities that they favor promoting integration over protecting competition. The courts have granted states the
ability to regulate the market in ways that promote other policy goals even if those
ways may harm competition.210 In Parker v. Brown, the Supreme Court granted states
the ability to offer state action immunity, which would displace the antitrust laws in
favor of public supervision, so long as their actions did not unduly burden interstate
commerce or violate the Constitution.211 States seeking to exempt nonsovereign private actors from state and federal antitrust enforcement must demonstrate that the
exemption arises from a “clearly articulated and affirmatively expressed . . . state
policy” and that the policy is “actively supervised by the State.” 212 States can grant
non-sovereign entities immunity through a range of actions including direct legislation, agency action, or by granting a certificate of public advantage (COPA). Currently, thirteen states have statutes authorizing the state to grant a COPA or state
action immunity.213
It is unclear whether state action immunity has successfully promoted beneficial
integration while protecting competition. In recent years, use of state action
immunity has come under significant scrutiny, especially in health care, as several
states had granted immunity without proper articulation of state purpose or

210. See Phillip Areeda, Antitrust Immunity for “State Action” After Lafayette, 95 HARV.
L. REV. 435, 436 (1981).
211. Parker v. Brown, 317 U.S. 341 (1943); see also Areeda, supra note 210, at 436 n.5.
212. N.C. Bd. of Dental Exam’rs v. FTC, 135 S. Ct. 1101, 1110 (2015). For a more indepth discussion of North Carolina Board of Dental Examiners v. FTC, see Marie Forney,
Note, North Carolina State Board of Dental Examiners v. FTC: Aligning Antitrust Law with
Commerce Clause Jurisprudence Through a Natural Shift of State-Federal Balance of Power,
92 IND. L.J. 365 (2016).
213. State statutes authorizing COPAs include the Idaho Health Planning Act, IDAHO CODE
ANN. § 39-4903 (2011); the Kansas Health Care Provider Cooperation Act, KAN. STAT. ANN.
§§ 65-6801 to -6809 (2002); the Maine Hospital Cooperation Act, ME. REV. STAT. ANN. tit.
22, § 1844 (Supp. 2015); MISS. CODE. ANN. § 41-9-307 (West 2007); the Montana Health &
Safety Code, MONT. CODE ANN. § 50-4-603 (2015); the Nebraska Health Care FacilityProvider Act, NEB. REV. STAT. ANN. §§ 71-7701 to -7711 (LexisNexis 2014); the New York
Public Health Law, N.Y. COMP. CODES R. & REGS. tit. 10, § 83-2 (2014); the North Carolina
Hospital Cooperation Act, N.C. GEN. STAT. ANN. § 131E-192.4 (West 2010); the South
Carolina Health Care Cooperation Act, S.C. CODE ANN. § 44-7-530 (2002); TENN. CODE ANN.
§ 68-11-1303 (2013); TEX. HEALTH & SAFETY CODE ANN. § 314.002 (West 2016); VA. CODE
ANN. § 15.2-5384.1 (2012); and WIS. STAT. ANN. § 150.85 (West 2016).
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supervision.214 Robert Berenson and Randall Bovbjerg performed an extensive case
study of a COPA granted in North Carolina that enabled Mission Health System
(“Mission”) in Asheville to acquire its major rival, St. Joseph’s Health System. 215
North Carolina granted Mission a COPA in exchange for an agreement to a “quasiregulatory” regime that controlled Mission’s overall profit margins, its average
inpatient and outpatient costs, and the share of primary physicians it could employ.216
After analyzing years of data, the researchers were unable to conclude that the COPA
effectively counteracted the loss of competition in the area, but they did find that the
model had some successes and with modifications “a COPA-like approach could
provide a useful complement to antitrust enforcement in addressing market
power.”217
If carefully limited and executed properly, a COPA may offer a state several benefits over antitrust enforcement alone. First, it could give states the ability to experiment with vertical integration in health care in ways that attempt to balance the benefits of clinical integration with the risks to competition. Second, protection from
antitrust prosecution offers health care entities further incentive to submit to data
reporting and monitoring that can provide essential information on the impact of vertical integration in different market conditions. Such data would also enable states to
monitor the impact of various forms of antitrust immunity on price or utilization as
a result of a merger over time. Finally, properly executed state action immunity could
offer the opportunity to closely monitor and regulate far more health care entities
than federal enforcement agencies could cover alone and for longer periods of time
than conduct remedies.
But the state must have a clearly defined regulatory body assigned to monitor and
regulate the entities, as well as the financial and personnel resources to do so. A
COPA that grants antitrust immunity without appropriate oversight risks significant
harm to consumers. In fact, federal antitrust enforcement officials have recently
raised significant concerns about whether state action immunity may do more harm
than good.218 Edith Ramirez, Chairwoman of the FTC, expressed concerns that in
some states the grant of antitrust immunity in an effort to promote collaboration and
integration “betrays a misunderstanding of the crucial role that competition plays in
the healthcare sector.”219 She reiterated the careful balancing that federal antitrust
enforcement agencies conduct when reviewing a proposed merger or collaboration,

214. See, e.g., N.C. Bd. of Dental Exam’rs, 135 S. Ct. at 1115 (finding North Carolina did
not sufficiently supervise the Board of Dental Examiners); FTC v. Phoebe Putney Health Sys.,
Inc., 133 S. Ct. 1003 (2013).
215. See BERENSON & BOVBJERG, supra note 161, at 8.
216. See id. at 1.
217. Id. at 16, 25.
218. See Ramirez, supra note 139, at 2245; Staff Comment, Fed. Trade Comm’n, Letter to
Ctr. for Health Care Pol’y and Res. Dev. re: Certificate of Pub. Advantage Applications Filed
Pursuant to N.Y. Pub. Health L., N.Y. COMP. CODES R. & REGS. tit. 10, § 83-2 (2015), https://
www.ftc.gov/system/files/documents/advocacy_documents/ftc-staff-comment-center-health-care
-policy-resource-development-office-primary-care-health-systems/150422newyorkhealth.pdf
[https://perma.cc/X8YQ-R3TA].
219. Ramirez, supra note 139, at 2246.
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including a weighing of the procompetitive and anticompetitive effects of a proposed
integration.220 Without careful supervision and narrowly defined limits on the scope
of antitrust immunity, COPAs and grants of state action immunity risk exacerbating
antitrust concerns rather than ameliorating them.
The FTC further demonstrated its skepticism of COPAs and state action immunity
recently with respect to New York’s COPA for health care collaboratives. 221 In reviewing an application for a COPA, New York considers (1) the potential benefits
of the health care provider collaborative activities, including preservation of needed
health care services, improvement in quality and access to services, lower costs, and
improvements in payment methodologies; (2) the health care provider landscape;
(3) the potential disadvantages of the collaborative activities; (4) the availability of
alternatives that would be less harmful to competition; and (5) the extent to which
active supervision will mitigate the risks associated with the collaboration.222 Despite
its review process, New York’s COPA immunity raised substantial concerns at the
FTC that such immunity would promote anticompetitive behavior arising from
healthcare integration.223 On April 22, 2015, the FTC sent a letter to the Center for
Health Care Policy and Resource Development in New York, claiming that the FTC
fully recognized the potential procompetitive benefits that can arise from health care
collaborations but that the COPA exemptions “are based on inaccurate premises
about the antitrust laws and the value of collaboration among health care providers.”224 The FTC found that a COPA was unnecessary to enable providers to engage
in procompetitive collaborative activities, but it threatened to “immunize conduct
that would not generate efficiencies and therefore not pass muster under the antitrust
laws.”225 The FTC went on to argue that the COPA risked increasing health care costs
and decreasing access to consumers in New York. States considering offering state
action immunity through legislation or a COPA program must be aware of FTC’s
concerns and carefully condition the immunity on significant data reporting requirements, regulatory oversight, and explicit boundaries of antitrust exemption. 226
In general, while we favor incentivizing health insurers and providers to provide
price and quality data, we remain skeptical that offering immunity to state and federal
antitrust laws is an advisable means of doing so. States with no other options should
consider creating clear price, quality, and concentration thresholds that would trigger
revocation of the immunity.
States must determine how to best employ their antitrust laws to promote

220. See id.
221. See Fed. Trade Comm’n, Letter to Ctr. for Health Care Pol’y and Res. Dev., supra
note 218.
222. N.Y. COMP. CODES R. & REGS. tit. 10, § 1003.14 (2015).
223. See Fed. Trade Comm’n, Letter to Ctr. for Health Care Pol’y and Res. Dev., supra
note 218. The entities applying for the COPA at issue were part of the Delivery System Reform
Incentive Program for Medicaid recipients; however, the COPA program applies to all health
care provider collaborations, including ACOs.
224. Id. at 1.
225. Id. (emphasis in original).
226. See Fed. Trade Comm’n, Letter to Ctr. for Health Care Pol’y and Res. Dev., supra
note 218.
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competition and efficiency in the health care markets. Data collection and analysis
of health care prices, insurance premiums, utilization rates, and quality of care will
be essential to this effort. Such data would enable state officials to identify
anticompetitive collaborations as early as possible, and seek to revoke immunity or
engage in some form of antitrust enforcement if entities violated the terms of the
immunity. While states have a significant role to play in antitrust enforcement, as
Robert Berenson previously noted, antitrust enforcement “can only be one—and not
the primary—approach to addressing provider pricing power.” 227
C. ACO Certification
To monitor the impact of vertical integration on price, quality, and competition,
state certification programs can offer a more comprehensive and preferable alternative to COPAs and state action immunity. Unlike the regulatory approval and reporting requirements for Medicare ACOs, there is no regime of oversight for commercial
ACOs. States can take a more active role overseeing health care integration, particularly commercial ACOs, by creating Certificate of Authority programs. States can
tailor the Certificate of Authority requirements to enable them to achieve their
particular policy goals. Key considerations include determining which state entity
will oversee the certification, whether certification will be mandatory or voluntary,
whether to require antitrust and solvency reviews, what price and quality disclosures
to require, and whether to incentivize integration by granting antitrust immunity and
exemptions to other state laws.228 Certification programs also allow states to review
these features of any particular ACO both prior to certification and on an ongoing
basis. Gathering historical and ongoing price and quality data will enable states to
monitor market dynamics, inform future decisions regarding integration, and support
antitrust enforcement actions.
To date, three states have established Certificate of Authority programs for commercial ACOs—Texas, Massachusetts, and New York.229 The features of the three
different programs reflect each state’s goals and concerns. Certification presents essentially a quid pro quo, where the state offers a range of benefits to the integrating
entity—typically an ACO—in exchange for a more in-depth review up front and
continued oversight.230 Massachusetts has a voluntary ACO Certification Program

227. Robert Berenson, Addressing Pricing Power in Integrated Delivery: The Limits of
Antitrust, 40 J. HEALTH POL. POL’Y & L. 711, 714 (2015).
228. HOLLINGSHEAD ET AL., supra note 186, at 14–16.
229. These programs are Massachusetts Health Policy Commission (HPC), MASS. GEN.
LAWS ANN. ch. 6D, § 2 (West 2016); New York Certificates of Authority, N.Y. COMP. CODES
R. & REGS. tit. 10, § 1003.6 (2015); and Texas Health Care Collaboratives (HCC), TEX. INS.
CODE ANN. § 848 (West 2009).
230. See, e.g., MASS. GEN. LAWS ANN. ch. 6D, § 2 (West 2016) (setting forth duty of HPCs
to monitor health care delivery and payment); N.Y. COMP. CODES R. & REGS. tit. 10, § 1003.1
(2015) (setting forth data reporting requirements for ACOs); TEX. INS. CODE ANN. § 848.106
(Supp. 2016) (setting forth quality and cost monitoring requirements for HCCs). New York
only certifies non-risk-bearing ACOs. Organizations that bear insurance risk or manage care,
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governed by the Massachusetts Health Policy Commission. ACOs seeking certification must satisfy several minimum standards, including the use of alternative payment methodologies, providing medical and behavioral health services across the
continuum, and allowing for health care price transparency in exchange for an HPC
“seal of approval” and the opportunity for preferential contracting with state-funded
insurance contracts.231 As to data gathering, HPC already requires all provider organizations of a certain size and scope to register and submit data on costs and
charges to the Center for Health Information and Analysis, but any ACO applying
for certification must also register as a provider and disclose such information regardless of size or scope.232 While the ACO certification process and its requirements
are still under development, HPC has yet to require a solvency review or offer further
potential incentives for ACO formation, such as immunity or a safe harbor from state
and federal antitrust laws, exemption from state self-referral, or other consumer protection laws.233 According to staff members at HPC, a seal of approval from the state
“is a meaningful distinction in a competitive marketplace, such as Massachusetts,” 234
which may provide sufficient incentive for ACO certification, negating the need for
the state to grant such legal exemptions.
In Texas, the Department of Insurance governs the certification of Health Care
Collaboratives (HCCs), Texas’s version of ACOs. 235 Certification is mandatory for
the HCC to take on certain levels of financial risk, and the program focuses mostly
on the antitrust implications of HCCs.236 To obtain certification, an HCC must
demonstrate the willingness and ability to increase collaboration and integration
among health care providers; promote improvements in care quality and outcomes;
reduce preventable medical errors; contain costs without jeopardizing quality; and
gather, analyze, and report statistics on health care costs, quality, access, and utilization.237 In addition, the HCC must fund and engage in an in-depth antitrust review
that provides evidence that the proposed collaboration is not likely to harm competition and that the procompetitive effects of the collaboration outweigh any anticompetitive effects of increased market power.238 Having the applicants fund the reviews saves state resources, but may also discourage health care entities from

as defined under New York insurance law, must receive an appropriate license. N.Y. COMP.
CODES R. & REGS. tit. 10, § 1003.1.
231. See MASS. GEN. LAWS ANN. ch. 6D, § 15 (West 2016) (setting forth standards for
certification as an ACO in Massachusetts); HOLLINGSHEAD ET AL., supra note 186, at 14.
232. MASS. GEN. LAWS ANN. ch. 6D, § 15.
233. Id.; HOLLINGSHEAD ET AL., supra note 186, at 17.
234. HOLLINGSHEAD ET AL., supra note 186, at 14 (quoting from interviews conducted by
the authors with key officials at HPC).
235. See, e.g., TEX. INS. CODE ANN. §§ 848.056–57 (West 2009) (providing requirements
for application for certification of authority and approval of that application); id. § 848.201
(establishing basis for state enforcement actions against an HCC).
236. HOLLINGSHEAD ET AL., supra note 186, at 15.
237. TEX. INS. CODE ANN. § 848.057; see also HOLLINGSHEAD ET AL., supra note 186, at
15 (stating that depending on complexity and extent, review costs could range from $25,000
to $250,000 for the initial review and up to $10,000 per annual renewal).
238. TEX. INS. CODE ANN. § 848.057(a)(5)–(6).
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forming HCCs. To date, no health care provider organization has applied for certification as an HCC in Texas, and so whether this type of certification serves to protect
competition or discourage integration remains uncertain.
In contrast to Massachusetts and Texas, New York’s voluntary certificate of authority for commercial ACOs both demands more of and offers more to applying
ACOs. New York encourages clinical and financial integration by offering to exempt
qualifying ACOs from prosecution under the corporate practice of medicine doctrine,
state and federal antitrust laws, and prohibitions on fee splitting and self-referrals.239
In exchange, the ACO must agree to “[p]rovide, manage and coordinate health
care . . . for a defined population . . . ; [b]e accountable for quality, cost, and delivery
of health care to ACO patients; [n]egotiate, receive and distribute any shared savings
or losses; and [e]stablish, report and ensure provider compliance with health care
criteria including quality performance standards.”240 In addition to the materials requested for initial certification application, ACOs applying for a COPA must submit
any additional information requested by the state during the COPA review process
described above.241
State certification of ACOs offers a means of incentivizing beneficial integration
in health care while offering states the opportunity to gather valuable cost and quality
data to determine the impact of such integration on the dynamics in the health care
markets. States considering certification should monitor the success of
Massachusetts, Texas, and New York to determine which elements of their programs
to emulate. The design of an ACO certification program entails policy tradeoffs. For
instance, mandatory certification enables states to guarantee oversight and access to
essential cost and quality data, but it may create substantial barriers to ACO formation, which states may still want to encourage. By contrast, the promise of state
action immunity via a COPA may encourage ACO formation, but it may also unduly
protect entities that engage in anticompetitive behavior and abuse market power. Finally, voluntary certification programs that do not offer significant benefits may not
enroll many ACOs, which would significantly hinder the state’s ability to monitor
and regulate the activities of integrating health care entities.
D. Rate Oversight Authority
A step beyond ACO certification models that only apply to certain forms of integration is to vest more widespread rate oversight authority in a rate oversight body.
There are two models of oversight authority: (1) an independent rate commission that
reviews and oversees provider rates; or (2) expanding the insurance rate review authority of the state department of insurance. Authorities under both models can be
vested with a spectrum of authority ranging from weaker reporting or recommendation power to stronger rate approval and enforcement power. To be effective, however, the rate oversight body should be insulated from capture by the providers or
insurers it regulates and possess regulatory and enforcement authority to limit rate
increases.

239. See HOLLINGSHEAD ET AL., supra note 186, at 14–15.
240. N.Y. COMP. CODES R. & REGS. tit. 10 § 1003.6(b) (2015).
241. See supra notes 221–25 and accompanying text.
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1. Rate Oversight Commission
States can establish an independent rate oversight commission to oversee providers’ health care prices and transactions in their state. A rate oversight commission’s
charge typically includes authority to study and make recommendations on proposed
health care mergers and to monitor prices and quality data postmerger. But a more
powerful oversight model vests the oversight commission with regulatory authority
to enforce and limit excessive provider prices.
In states that have established an APCD, a commission could have authority to
analyze statewide claims data from the APCD to evaluate the pricing power, efficiency, utilization, and quality of the existing provider landscape. Based on its findings, the commission then makes recommendations and supplies data to both the
state’s attorney general regarding proposed mergers or anticompetitive provider behavior and policy-making bodies regarding the need for regulatory intervention. 242
For example, if the commission observes that powerful providers are using antitiering provisions in contracts with health plans to limit the ability of those health
plans to steer members to lower cost or higher value providers, the commission could
recommend enforcement action by the state attorney general, or legislation prohibiting anti-tiering clauses in provider-plan contracts. A rate oversight commission also
could be given more direct regulatory authority beyond simply monitoring and making recommendations. For example, it might be granted the ability to implement price
caps if prices rise beyond certain supracompetitive thresholds.
To date, five states have established a rate-oversight commission: Delaware,
Maryland, Massachusetts, New York, and Pennsylvania. 243 Perhaps the most prominent example of such a body is the Massachusetts Health Policy Commission. In
terms of rate oversight, HPC has some regulatory authority, with the ability to require
providers that exceed cost growth benchmarks to implement performance improvement plans and fine them if the provider fails to comply. 244 Along with HPC, rate
oversight commissions in Delaware, New York, and Pennsylvania have authority to
analyze price and cost data and make recommendations. 245 The commission in
Maryland, by contrast, has additional authority to approve and set inpatient and

242. An example is Pennsylvania’s Health Care Cost Containment Council, which has the
authority to collect, analyze, and make recommendations on health care price data. See 35 PA.
STAT. AND CONS. STAT. ANN. § 449.17b (West Supp. 2016); NASI PANEL ON PRICING POWER,
supra note 26, at 42.
243. See DEL. CODE ANN. tit. 16, § 9902 (West 2003) (establishing the Delaware Health
Commission); MD. CODE ANN., HEALTH–GEN. § 19-720 (LexisNexis 2015) (establishing the
state Health Services Cost Review Commission); MASS. GEN. LAWS ANN. ch. 6D, § 2 (West
2016) (establishing the Massachusetts Health Policy Commission); N.Y. INS. LAW § 213
(McKinney 2015) (establishing the New York State Health Care Quality and Cost
Containment Commission); 35 PA. CONS. STAT. AND CONS. STAT. ANN. § 449.17b (West Supp.
2016) (establishing the Health Care Cost Containment Council).
244. MASS. GEN. LAWS ANN. ch. 6D, § 3; see also NASI PANEL ON PRICING POWER, supra
note 26, at 42.
245. See supra note 242.
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outpatient rates and limit hospitals’ total revenues.246 In addition, in 2015 Colorado
established a health care cost-containment commission with a three-year mandate to
study the drivers of health care cost growth, analyze the state’s APCD and insurance
rate review data, and make recommendations to the legislature. 247
A significant challenge to the effectiveness of an independent rate oversight commission is protecting the body from regulatory capture.248 In particular, it is important
to insulate the commission from undue influence from health care providers and
powerful health systems who will resist oversight efforts and commission recommendations that scrutinize or threaten their market power and pricing practices. The
Massachusetts HPC, for example, was structured to avoid capture by requiring diverse representation, including those with experience as a health administrator, a
health economist, a physician, and a representative from a variety of perspectives
including consumer advocates, health insurance, health care workforce, and labor
unions, among others.249 In addition, the members of the HPC may not be employed
as a state executive branch official and may not be employed by, affiliated with, serve
as a board member, or have a financial stake in any health care provider.250
Another challenge is making sure the rate oversight commission coordinates with
other existing government agencies and does not just add another regulatory body to
the mix.251 To be effective, a commission must closely communicate with the APCD
authority, the state attorney general, the department of insurance, certificate-of-need
authorities, and others. Although it can be extremely valuable for a state to have an
expert, independent commission to analyze APCD data and make policy or enforcement recommendations, the most effective model of rate oversight commission must
be vested with meaningful regulatory and enforcement authority—whether it is the
power to approve provider budgets, impose limits on excessive prices or price increases, or engage in rate regulation.
2. Insurance Rate Review
States could also increase the insurance rate review authority of the department
of insurance. The ACA requires states to review proposed insurance rates for nongrandfathered health plans and determine the reasonableness of any proposed rate

246. MD. CODE ANN., HEALTH-GEN. §§ 19-219 to 19-221 (LexisNexis 2015) (providing
authority for the Maryland’s Health Services Cost Review Commission (HSCRC) to review
and set hospital rates); MD. CODE ANN., INS. § 15-604 (LexisNexis 2015) (requiring all payers
to reimburse Maryland hospitals based on the rates established by the HSCRC). For a further
discussion of Maryland’s all-payer rate setting program, see infra Part IV.F.
247. See COLO. REV. STAT. ANN. § 25–46–101 to 105 (West Supp. 2015) (establishing the
Colorado Commission on Affordable Health Care).
248. See generally Rachel E. Barkow, Insulating Agencies: Avoiding Capture Through
Institutional Design, 89 TEX. L. REV. 15 (2010).
249. MASS. GEN. LAWS ANN. ch. 6D, § 15.
250. Id. § 2.
251. See 35 PA. STAT. AND CONS. STAT. ANN. § 449.17b (West Supp. 2016) (creating an
oversight commission with members who are appointed by the Governor and members of the
legislature); NASI PANEL ON PRICING POWER, supra note 26, at 42.
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increase of more than 10%, but it does not require states to give prior-approval (or
disapproval) authority over such rate hikes to the department of insurance. 252 Pursuant to these requirements, many states strengthened their insurance rate review functions. States with prior-approval authority require health insurers to submit their rates
to the department of insurance for prior approval, and the insurance commissioner
has the authority to reject or reduce proposed rate increases. 253 Other states give the
insurance commissioner weaker “file-and-use” authority, where rates go into effect
once they have been filed and the department has no ability to reject the rate increase.254 States also vary in terms of which types of health insurance products (e.g.,

252. 42 U.S.C. § 300gg–94(c) (2012); 45 C.F.R. § 154.200 (2015). If the state does not
establish an effective rate review authority, the Department of Health and Human Services
shall determine the reasonableness of the proposed rate increase above 10%, but it does not
have the authority to disapprove the rate. For more on the ACA’s insurance rate review requirements and state rate review activities, see generally John Aloysius Cogan Jr., Health
Insurance Rate Review, 88 TEMPLE L. REV. 411 (2016).
253. “Prior approval” authority generally means that the state insurance commissioner can
approve, reject, or reduce proposed rate increases from insurers. If a rate is not disapproved or
reduced by a deadline, it goes into effect. COMMUNITY CATALYST, RATE REVIEW: WHAT IS IT
AND WHY DOES IT MATTER? 2 (2013), http://www.communitycatalyst.org/resources
/publications/body/Rate-review-fact-sheet-FINAL.pdf [https://perma.cc/7E8G-CE4G]. The
following states vest the insurance commissioner with prior approval authority: Alabama,
ALA. CODE § 27-2-17 (LexisNexis 2014); Alaska, ALASKA STAT. § 21.51.405 (2014);
Arkansas, ARK. CODE ANN. § 23-79-109 (Supp. 2015); Colorado, COLO. REV. STAT. ANN. §1016-107 (West Supp. 2015); Delaware, DEL. CODE ANN. tit. 16, §§ 9902–9903 (Supp. 2014);
Hawaii, HAW. REV. STAT. ANN. § 431:14G-105 (West Supp. 2016); Indiana. IND. CODE § 278-4-7 (2012); Iowa, IOWA CODE ANN. § 514A.13 (West 2015); Kansas, KAN. STAT. ANN. § 402215 (Supp. 2015); Kentucky, KY. REV. STAT. ANN. § 304.17-380 (LexisNexis 2011)),
Maryland, MD. CODE ANN. HEALTH–GEN. § 19-108 (LexisNexis 2015); Massachusetts, MASS
GEN. LAWS ch. 6D § 2 (West 2016); Michigan, MICH. COMP. LAWS ANN. § 550.1607 (West
Supp. 2016); Minnesota, MINN. STAT. ANN § 62A.02 (West Supp. 2016); Mississippi, MISS.
CODE ANN. § 83–9–3 (West Supp. 2015); Nebraska, NEB. REV. STAT. ANN. § 44-710
(LexisNexis Supp. 2015); Nevada, NEV. REV. STAT. ANN. § 686B.070 (LexisNexis 2014);
New Hampshire, N.H. REV. STAT. ANN. § 415:1 (2015); New Mexico, N.M. STAT. ANN.
§ 59A-18-13.2 (West Supp. 2015); New York, N.Y. INS. LAW § 213 (McKinney 2015); North
Carolina, N.C. GEN. STAT. ANN. § 58-51-95 (West Supp. 2015); North Dakota, N.D. CENT.
CODE § 26.1-17-26 (2010); Ohio, OHIO REV. CODE ANN. § 3923.021 (LexisNexis 2010);
Oklahoma, OKL. STAT. ANN. tit. 36 § 2606 (West 2011); Oregon, OR. REV. STAT. § 743.018
(2015); Tennessee, TENN. CODE ANN. § 56-26-102 (Supp. 2015); Vermont, VT. STAT. ANN.
tit. 8 § 4062 (2015); and West Virginia, W. VA. CODE ANN. § 16-29B-1 (LexisNexis Supp.
2016).
254. “File-and-use” authority generally means that the insurance companies must file their
proposed rates with the department of insurance, but the rates may go into effect without department approval. The department may have the ability to go back and disapprove a rate
increase that was later deemed unreasonable, usually triggered by a consumer complaint process. COMMUNITY CATALYST, supra note 253, at 2. The following states vest the insurance
commissioner with file-and-use authority: Arizona, ARIZ. REV. STAT. ANN. § 20-1342.02
(2010); Illinois, 235 ILL. COMP. STAT ANN. 93/25 (West 2008); Louisiana, LA. STAT. ANN.
§ 22:972 (2009); Missouri, MO. ANN. STAT. § 354.152 (West 2015); Montana, MONT. CODE
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individual, group, HMOs, PPOs) are subject to their rate-review requirements.255 Recent research suggests states with stronger forms of rate review authority, such as
prior-approval authority and loss-ratio requirements, experienced lower premium increases in the individual market than states without rate review authority or with only
file-and-use authority.256
Although insurance rate review focuses on premium rate increases rather than on
provider prices, limiting the ability of insurance companies to raise premiums puts
pressure on providers negotiating with the health plans. 257 When health plans are
limited in their ability to raise premiums, they cannot simply pass high provider
prices on to the policy holders. But most state insurance rate review systems, even
as augmented by ACA requirements, are generally inadequate to offset some insurers’ lack of bargaining power relative to powerful providers.
To really get at provider pricing power, insurance rate review must be further
strengthened by giving the insurance commissioner authority to condition approval
of insurance rates on mandatory limits on provider price increases. For instance,
Rhode Island has expanded its insurance department’s authority to limit annual price
increases for inpatient and outpatient services. 258 The state caps the amount of price
increases to which insurers can contractually agree to the Consumer Price IndexUrban plus 1%.259 Rhode Island’s cap on the rate increases insurance plans may accept from providers is a form of indirect provider rate caps via health insurance rate
review.
The advantages of strengthening insurance rate review authority are that stronger
forms of insurance rate review may be effective at constraining premium growth,

ANN. § 33-22-156 (2015); New Jersey, N.J. STAT. ANN. § 17B:18-5 (West 2013); South
Carolina, S.C. CODE ANN. § 38-71-310 (2015); Texas, TEX. INS. CODE ANN. § 1507.008 (West
2009); Utah, UTAH CODE ANN. § 31A-22-602 (LexisNexis 2014); and Virginia, VA. CODE
ANN. § 38.2-316.1 (2015).
255. The following states vest prior approval authority in the insurance commissioner only
for subsets of the insurance market: Connecticut, CONN. GEN. STAT. ANN. § 19a-638 (West
2011); Florida, FLA. STAT. ANN. § 627.410 (West 2016); Georgia, GA. CODE ANN. § 33-21-13
(2014); Idaho, IDAHO CODE § 41-5206 (2010); Maine, ME. REV. STAT. ANN. tit. 24-A, § 2736
(2015); Pennsylvania, 35 PA. STAT. AND CONS. STAT. ANN. § 449.17b (West Supp. 2016);
Rhode Island, 4D R.I. GEN. LAWS § 27-18-54 (2008); South Dakota, S.D. CODIFIED LAWS
§ 58-17-4.1 (2004); Washington, WASH. REV. CODE ANN. § 48.44.020 (West 2014);
Wisconsin, WIS. STAT. ANN. § 625.11 (West 2006); and Wyoming, WYO. STAT. ANN. § 2618-135 (2015).
256. Pinar Karaca-Mandic, Brent D. Fulton, Ann Hollingshead & Richard M. Schaffer,
States with Stronger Health Insurance Rate Review Authority Experienced Lower Premiums
in the Individual Market, 34 HEALTH AFF. 1358, 1360 (2015).
257. See NASI PANEL ON PRICING POWER, supra note 26, at 44.
258. 6C R.I. GEN. LAWS § 42-14.5-3 (Supp. 2015); CODE R.I. REG. 4424 (2012).
259. See R.I. Office of the Health Ins. Comm., Reg. 17, Sec. 7.e (setting affordability standards that include limits on hospital rate increases as a condition of health insurance rate
approval), http://www.ohic.ri.gov/documents/Regulation-17-Filing-of-Forms-and-Rates.pdf
[https://perma.cc/29UW-RUBH]. The rules limit hospital price increases to the CPI-Urban
less Food and Energy for the Northeast Region (CPI-U) plus 1%, decreasing to CPI-U plus
0% by 2018. See Cogan, supra note 252, at 463 n.297.
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which may be especially important as the insurance market becomes more concentrated.260 A significant advantage is that insurance rate review builds on a state’s
existing institutions and infrastructure. In addition, even in states without an APCD,
the insurance commissioner has extensive authority to gather private price and claims
data from payers in the state. To be effective, however, most states would have to
augment the authority of the insurance commissioner, as Rhode Island did, to explicitly place limits on provider price increases as part of its insurance rate review
authority.261
Without the authority to impose limits on provider prices, a major limitation of
most states’ insurance rate review system is that the standards for reviewing rate
increases are not calibrated to address providers’ pricing power but rather get at antiquated property-casualty insurance market problems, such as financial solvency.262
Another challenge of insurance rate review is the scope of most states’ laws and the
ACA are too limited and may not apply to all health insurance products by excluding,
for example, for-profit, employer-based, or large-group plans.263 In addition, it is unclear how existing rate review authority will apply to provider-risk-bearing organizations, such as ACOs or conglomerates consisting of health systems with a health
plan. Another risk is that stronger limits on insurers’ premium revenue without addressing provider pricing power may drive insurers to fold or exit the market. Finally,
to the extent insurance rate caps or targets are based on averages, they may widen
the gap between the “must-have” and “have-not” providers.264 Must-have health systems may still command monopoly prices, but to get under the cap, the insurers may
force less powerful providers to lower prices below sustainable levels or exit the
market.
In sum, the existing rate review authority in most states will not likely provide
sufficient levers to oversee and contain the pricing power of integrated providers.
However, states can follow Rhode Island’s example and build on the existing

260. Karaca-Mandic et al., supra note 256, at 1365; Healthy Competition? An Examination
of the Proposed Health Insurance Mergers and the Consequent Impact on Competition:
Hearing Before the Subcomm. on Regulatory Reform, Commercial and Antitrust Law of the
H. Comm. on the Judiciary, 114th Cong. (2015), https://judiciary.house.gov/wp-content
/uploads/2016/02/114-47_96274.pdf [https://perma.cc/ASS3-W8AW] (written statement of
Jaime S. King, Professor of Law at the University of California, Hastings College of Law).
261. See supra notes 258–59 and accompanying text.
262. John Cogan delves extensively into the post-ACA insurance rate review system and
concludes:
Since the states, and now the federal government, apply to health insurance a rate
review standard designed to address a set of market failures that existed a hundred
years ago for a different insurance product, the health insurance rate review process
is simply incapable of controlling the fundamental problems that plague today’s
health insurance market—the market failures leading to excessive provider prices.
As such, rate review can do little to control the medical cost component of health
insurance rates. Simply put, there is a mismatch: health insurance rate review uses
the wrong tools for the job at hand.
Cogan, supra note 252, at 415 (emphasis in original).
263. See id. at 469.
264. See NASI PANEL ON PRICING POWER, supra note 26, at 44.
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infrastructure and expertise of the insurance department to provide insurance
commissioners regulatory authority over private provider rate increases.
E. Private Rate Caps
As an intermediate step before full-fledged rate regulation and in conjunction with
the establishment of a rate oversight authority, a state could cap providers’ private
health care prices. The cap would apply to all private payers, including out-ofnetwork payments and self-pay patients.265 In many proposals, price caps are set as
a percentage of Medicare rates. For example, health economics and policy experts
from Dartmouth suggested a private price cap of 125% of Medicare rates;266 Robert
Murray, former executive director of Maryland’s rate setting agency, suggested a cap
of 150–175% of Medicare rates.267 Recent analysis demonstrating that private
inpatient payments are, on average, 175% of Medicare payments may suggest that
maximum price cap levels may need to be even higher. 268 Alternatively, price caps
could be defined not by reference to Medicare rates but in terms of average or percentages of private prices. Such a price cap would require access to private price data
from an APCD or other database.269

265. Mark Hall & Carl Schneider, Price-Gouging by Doctors and Hospitals, HEALTH
REFORM WATCH (July 19, 2009), https://web.archive.org/web/20091211202230/http://
www.healthreformwatch.com/2009/07/19/price-gouging-by-doctors-and-hospitals/ [https://
perma.cc/N2HR-B6HE] (suggesting a price cap of 150% of Medicare prices for self-pay
patients).
266. Jonathan Skinner, Elliot Fisher & James Weinstein, The 125 Percent Solution: Fixing
Variations in Health Care Prices, HEALTH AFF. BLOG (Aug. 26, 2014), http://healthaffairs.org
/blog/2014/08/26/the-125-percent-solution-fixing-variations-in-health-care-prices/ [https://perma.cc
/6ZU5-9433] (“If every patient and every insurance company always had the option of paying
125 percent of the Medicare price for any service, we would effectively cap the worst of the
price spikes. No longer would the tourist checked out at the ER for heat stroke be clobbered
with a sky-high bill. Nor would the uninsured single mother be charged 10 times the best price
for her child’s asthma care. This is not just another government regulation, but instead a
protection plan that shields consumers from excessive market power.”).
267. See Robert Murray, The Case for a Coordinated System of Provider Payments in the
United States, 37 J. HEALTH POL. POL’Y & L. 679, 689 (2012) [hereinafter Murray, The Case
for a Coordinated System of Provider Payments]; Robert Murray, Health Servs. Cost Review
Comm’n, The Cost of Hospital Care: Experience from Maryland’s All-Payer Rate Setting
System, NAT’L HEALTH POL’Y F., at slide 21 (Oct. 8, 2010), http://www.hscrc.state.md.us
/documents/pdr/Presentations/TheCostofHospitalCareNHPFR_Murray2010-10-08.pdf [https://
perma.cc/U25A-RRJ2].
268. Thomas M. Selden, Zeynal Karaca, Patricia Keenan, Chapin White & Richard
Kronick, The Growing Difference Between Public and Private Payment Rates for Inpatient
Hospital Care, 34 HEALTH AFF. 2147, 2148–49 (2015) (finding that the differential between
average private rates have grown to 75% higher than Medicare rates in 2012, up from about
10% higher than Medicare in the period 1996–2001).
269. See, e.g., Robin Gelburd, The Need for a Comprehensive, Current, and MarketRepresentative Health Care Cost Benchmark, HEALTH AFF. BLOG (Oct. 7, 2014),
http://healthaffairs.org/blog/2014/10/07/the-need-for-a-comprehensive-current-and-market
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Rate caps offer several advantages. First, they can limit outlier prices at the top
end of the scale, while still allowing for some competition below the cap. 270 Rate
caps preserve the ability of providers to charge different prices from each other,
which allows providers to compete within this range on the basis of price or quality,
but the caps limit the extent of price variation by imposing a ceiling on prices. 271
Second, a broad cap on private payer rates would improve payers’ bargaining position to resist price increases by powerful providers or at least put a regulatory backstop on the degree to which such providers can charge monopoly prices. Third, rate
caps are simpler from a regulatory perspective than rate setting, where the administrative body has to set prices for each service, because rate caps piggyback on the
prices set in the Medicare system. 272
On the other hand, to the extent that rate caps piggyback on Medicare rates, they
incorporate all the flaws of the Medicare pricing system as well as its strengths. 273
Rate caps also do not eliminate inefficiencies and administrative costs of price discrimination by providers, the practice of charging different rates to different payers
for the same service.274 Rate caps should only be considered for noncompetitive markets, because any rate-cap level, even if supported by substantial expertise and data,
will not precisely replicate the maximum prices that would result in a competitive
market in equilibrium. Some have criticized rate caps and other forms of rate
regulation as potentially stifling financial incentives for innovation. 275 Rate caps are

-representative-health-care-cost-benchmark/ [https://perma.cc/2PR6-AVNB ] (proposing to
set a provider’s “usual, customary, and reasonable” (UCR) rates, used in fee disputes for outof-network and self-pay patients, to 80% of average charges drawn from a geographically
representative dataset of private prices, here, FairHealth.org); David Seltz, David Auerbach,
Kate Mills, Marian Wrobel & Aaron Pervin, Addressing Price Variation in Massachusetts,
HEALTH AFF. BLOG (May 12, 2016), http://healthaffairs.org/blog/2016/05/12/addressing-pricevariation
-in-massachusetts/ [https://perma.cc/QKG9-ZQ6J].
270. NASI PANEL ON PRICING POWER, supra note 26, at 46.
271. Erin C. Fuse Brown, Resurrecting Health Care Rate Regulation, 67 HASTINGS L.J. 85,
133 (2015).
272. Robert A. Berenson, Jonathan H. Sunshine, David Helms & Emily Lawton, Why
Medicare Advantage Plans Pay Hospitals Traditional Medicare Prices, 34 HEALTH AFF. 1289,
1295 (2015) (“Placing an upper limit on what a hospital or physician can charge as a
percentage above Medicare prices might provide a regulatory alternative to actually setting
the commercial rates themselves, likely a less intrusive and less resource-intensive endeavor,
especially if the out-of-network ceilings were set initially to affect only a small number of
especially high-price hospitals.”).
273. Gelburd, supra note 269 (critiquing a system of price caps based on Medicare prices
because Medicare may not be representative of costs or particular dynamics in certain markets,
such as for lower-volume providers).
274. Uwe E. Reinhardt, The Many Different Prices Paid to Providers and the Flawed
Theory of Cost Shifting: Is It Time for a More Rational All-Payer System?, 30 HEALTH AFF.
2125, 2128–29 (2011).
275. See, e.g., Michael A. Morrisey, Frank A. Sloan & Samuel A. Mitchell, State Rate
Setting: An Analysis of Some Unresolved Issues, 2 HEALTH AFF. 36, 36 (1983) (noting that
detractors of state rate setting say that rate setting stifles innovation).
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politically challenging as well; they are likely to be opposed by the most powerful
providers whose pricing power will be limited by the caps. Caps may be supported,
however, by health plans, employers, and other purchasers of health care because
they could constrain the cost of including must-have providers in health plan
networks.
To date, no state has implemented price caps, although Rhode Island’s insurance
rate caps276 and West Virginia’s now-defunct hospital rate review program277 resemble the price caps described here.278
Price caps are often viewed as an intermediate, less intrusive alternative to ratesetting to limit unwarranted price variation especially among dominant providers.
Nevertheless, some administrative infrastructure must be established to determine
whether to implement a price cap or how to set the cap. States will require data from
an APCD and perhaps a rate oversight commission with expertise to come up with
the price cap levels and methodology.
F. Provider Rate Regulation
In highly concentrated provider markets where provider conglomerates are exercising unchecked market power, states can address provider pricing power through
direct regulation of provider prices. Different versions of rate regulation are discussed below: all-payer rate setting exemplified by Maryland’s system; private rate
regulation as illustrated by West Virginia’s now-defunct rate-review authority; and
the move to incorporate rate setting into global budget initiatives.
1. All-Payer Rate Setting
The prototypical system of provider rate regulation is all-payer rate setting, which
would set the rate for all payers, whether private insurers, government programs, or
self-pay patients. To include Medicare in the all-payer model, the state must obtain
a waiver from the Centers for Medicare and Medicaid Services.279 Under an all-payer
system, either a rate setting commission or a representative body of payers negotiates

276. See supra text accompanying notes 258–59.
277. See supra text accompanying note 290–92.
278. In an effort to address persistent provider price variation in Massachusetts, a SEIUled ballot initiative in 2015–2016 proposed to limit providers’ private rates to a corridor 20%
above or 10% below the average price paid to all providers by that health plan for that service.
Massachusetts Fair Health Care Pricing Act, No. 15-19 (2015–2016 Mass. Ballot Initiatives),
http://www.mass.gov/ago/docs/government/2015-petitions/15-19.pdf [https://perma.cc/3CZ6-8D3Q].
The SEIU agreed to drop the ballot measure when the Massachusetts legislature passed a
compromise to create a fund to redistribute funds from higher- to lower-priced hospitals and
with the promise of more union jobs at the largest hospital system. Priyanka Dayal McCluskey
& Jim O’Sullivan, Deal Reached To Avert Ballot Question on Hospitals, BOS. GLOBE
|(May 25, 2016), https://www.bostonglobe.com/business/2016/05/25/deal-reached-avert-ballot
-question-hospitals/xDPLHx13YRUq89Qz8FMCXK/story.html [https://perma.cc/TZ8C-TG7K].
279. See Robert Murray, Setting Hospital Rates To Control Costs and Boost Quality: The
Maryland Experience, 28 HEALTH AFF. 1395, 1395–96 (2009).
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a uniform set of provider reimbursement rates. 280 Although traditionally applied to
hospital services, in its broadest form, rate setting could apply to all provider services
(whether hospital, physician, post-acute, lab, diagnostic, etc.).
Under the rate setting commission approach, the commission collects detailed information about costs, patient volumes, hospital finances, and services for each provider for use in rate setting.281 The best-known and only example of this public utility
model of rate setting is Maryland’s all-payer rate setting system, where an administrative body sets hospital rates.282 Maryland’s system has controlled hospital costsper-case, but it must be paired with global budgets or ACO-type mechanisms to limit
incentives to increase patient volume. In the 1970s, several states adopted rate setting
systems only to abandon them during the deregulatory era of the 1980s–90s when
managed care seemed to be constraining health care costs.283
For the second model of rate setting through collective negotiation, there are no
examples from the United States, but Japan, Germany, France, Switzerland, and
other OECD countries use this model. 284 This model combines the bargaining leverage of all payers together in an oligopsony. 285 To counteract provider pricing power,
insurers combine their bargaining power and collectively negotiate with each provider separately or with a consortium representing all providers. 286 For those concerned about concentration among health insurers, allowing payers to come together
to bargain collectively with providers is not the same as increasing concentration in
the insurance market. The individual health plans would still have to compete for
their own customers on the basis of premiums, provider networks, consumer experience, and other benefits.287
Although rate setting eliminates price discrimination by a single provider against

280. See Vladeck & Rice, supra note 13, at 1312–13.
281. Murray, The Case for a Coordinated System of Provider Payments, supra note 267,
at 686–88. The data collection and analysis is similar to that performed through an APCD and
could also be used for rate setting.
282. MD. CODE ANN., HEALTH-GEN. § 19-201 to 19-203 (LexisNexis 2015) (establishing
the Maryland Health Services Cost Review Commission (HSCRC)); §§ 19-219 to 19-221
(providing for the HSCRC’s authority to review and set hospital rates); MD. CODE ANN., INS.
§ 15-604 (requiring all payers to reimburse Maryland hospitals based on the rates established
by the HSCRC); MD. CODE REGS. 10.37.01–.37.12 (2016) (setting forth administrative rules
for hospital rate review and rate setting in Maryland); see also Murray, The Case for a
Coordinated System of Provider Payments, supra note 267, at 686.
283. John E. McDonough, Tracking the Demise of State Hospital Rate Setting, 16 HEALTH
AFF. 142, 145 (1997).
284. See Uwe E. Reinhardt, A Modest Proposal on Payment Reform, HEALTH AFF. BLOG
(July 24, 2009), http://healthaffairs.org/blog/2009/07/24/a-modest-proposal-on-payment-reform/
[https://perma.cc/YK3S-DXJV]; Reinhardt, supra note 274, at 2129; Vladeck & Rice, supra
note 13, at 1313.
285. Vladeck & Rice, supra note 13, at 1313.
286. See Austin Frakt, All-Payer Rate Setting and Health Reform’s Underpants Gnomes
Strategy, WASH. POST: WONKBLOG (June 2, 2011), http://www.washingtonpost.com/blogs
/wonkblog/post/all-payer-rate-setting-and-health-reforms-underpants-gnomes-strategy/2011
/06/02/AG3SfHHH_blog.html#pagebreak [https://perma.cc/FP6X-2KD3].
287. See id.
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its various payers, rate setting generally allows providers to charge different prices
from each other, which preserves some degree of competition. Competition can be
amplified by reporting providers’ percentage markup above the standard rate and
quality ratings to allow price and quality comparisons with other providers. 288 Somewhat like Medicare, this approach allows for price differences to reflect differences
in costs if, for example, the facility is a teaching hospital. 289 To the extent it encourages price and quality transparency, rate setting could also encourage competition
among providers on the basis of value, while still limiting the pricing power of dominant providers.
2. Private Rate Regulation
Until recently, West Virginia provided a different model of provider rate regulation through review of providers’ private prices.290 West Virginia established its
Health Care Authority in 1983 to gather information on health care costs and run the
state’s rate regulation and certificate of need programs to control health care costs
and capital expenditures.291 In 2016, West Virginia abolished the agency’s hospital
rate review authority,292 but we describe its system here as an example of a state
program to regulate private prices.
Under the prior system, West Virginia hospitals would submit a rate application
to the Authority with their proposed private rates and their cost information, and the
Health Care Authority could approve, disapprove, or seek modification of the hospital’s rates for private payers.293 West Virginia’s hospital rate review system excluded
Medicare rates (which would require a Centers for Medicare and Medicaid Services
(CMS) waiver) as well Medicaid and public employees’ insurance rates. 294 A hospital could accept a guaranteed or pre-approved rate increase by tying its proposed
increase to a benchmarking methodology, based on peer hospitals’ costs and charges,

288. See Murray, The Case for a Coordinated System of Provider Payments, supra note
267, at 683–84; Reinhardt, supra note 284; Uwe E. Reinhardt, The Pricing of U.S. Hospital
Services: Chaos Behind the Veil of Secrecy, 25 HEALTH AFF. 57, 65–66 (2006); Austin Frakt,
Simply Put: All-Payer Rate Setting, INCIDENTAL ECONOMIST BLOG (Apr. 8, 2011), http://
theincidentaleconomist.com/wordpress/simply-put-all-payer-rate-setting/ [https://perma.cc
/7CAW-X5EQ].
289. See Frakt, supra note 288; Reinhardt, supra note 284.
290. West Virginia’s was not an all-payer system, because it did not include Medicare and
Medicaid in its rate-setting authority.
291. W. VA. CODE ANN. § 16-29b-1 to -29 (West 1997 & Supp. 2016) (§ 16-29b-19 to -21a
repealed 2016); W. VA. CODE R. § 65-5-1 to -28 (1992).
292. S.B. 68, 2016 Leg., Reg. Sess. (W. Va. 2016) (enacted) (amending the powers granted
to the Health Care Authority in West Virginia).
293. W.VA. CODE ANN. § 16-29b-19 (repealed 2016).
294. ROBERT MURRAY & ROBERT A. BERENSON, HOSPITAL RATE SETTING REVISITED:
DUMB PRICE FIXING OR A SMART SOLUTION TO PROVIDER PRICING POWER AND DELIVERY
REFORM? 31 (2015), http://www.urban.org/sites/default/files/alfresco/publication-pdfs/2000516
-Hospital-Rate-Setting-Revisited.pdf [https://perma.cc/9YEY-AM8K].
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or it could apply for a greater rate increase subject to more in-depth review.295 Rather
than setting rates precisely for each hospital, West Virginia’s system effectively created a rate corridor with the authority-approved charge limit serving as the ceiling on
its privately negotiated prices and the hospital’s costs serving as the floor. 296 Under
this system, hospitals could negotiate different prices and payment methodologies
with different payers, preserving a degree of price variation and discrimination.
Under its private rate review system, West Virginia’s costs-per-case grew slower
than the national average, suggesting that it was somewhat effective at controlling
health care price growth.297 However, West Virginia’s inpatient and outpatient utilization rates were much higher than the national average, which drove the state’s relatively high per capita hospital spending.298 In any event, without rate review authority
and with new laws shielding hospital mergers and conduct from state and federal
antitrust liability,299 West Virginia has moved rapidly to remove oversight of hospital
pricing or competition.
3. Global Budgets
Newer rate setting approaches are moving to incorporate global budgets to simultaneously regulate prices and utilization for providers by imposing total revenue limits on health systems.300 States can prospectively set a global budget for an integrated

295. See ANNA S. SOMMERS, CHAPIN WHITE & PAUL B. GINSBURG, ADDRESSING HOSPITAL
PRICING LEVERAGE THROUGH REGULATION: STATE RATE SETTING 7 & 9 n.24 (2012),
http://nihcr.org/wp-content/uploads/2016/07/Policy_Analysis_No._9.pdf [https://perma.cc
/VN8A-QB38].
296. MURRAY & BERENSON, supra note 294, at 32 (“This corridor-based approach stands
in contrast to most other mandatory rate setting systems, such as Maryland, in which the approved rate largely acts as both a ceiling and a floor for a hospital and the hospital must adjust
its charges to be in compliance with that approved rate.”).
297. GRAHAM ATKINSON, COMMONWEALTH FUND, PUB. 1332, STATE HOSPITAL RATESETTING REVISITED 11 (2009) (“From 1985 to 2007, costs per [inpatient admission] in West
Virginia increased by 192 percent, compared with a nationwide increase of 213 percent.”);
MURRAY & BERENSON, supra note 294, at 38–39 (noting that in 2011, West Virginia had the
16th lowest hospital markups at 151% above costs, versus a national average markup of 220%
above costs, and that in 2012, West Virginia’s median gross price per inpatient discharge was
26% lower than the U.S. median).
298. See MURRAY & BERENSON, supra note 294, at 39.
299. See S.B. 68, 2016 Leg., Reg. Sess. (W. Va. 2016) (enacted) (amending the powers
granted to the Health Care Authority in West Virginia); John Kennedy, W. Va. Gov. Signs Bill
with Antitrust Exemptions for Hospitals, LAW360 (Mar. 21, 2016), http://www.law360.com
/articles/774171/w-va-gov-signs-bill-with-antitrust-exemptions-for-hospitals [https://perma.cc
/6UYR-NA6P].
300. Rachel Block, State Models for Health Care Cost Measurement: A Policy and
Operational Framework, MILBANK MEMORIAL FUND, at 7 (2015). Global budgets can also be
implemented by private payers, often called “Alternative Quality Contracts” or ACOs with
two-sided risk, or “Total Cost of Care Contracts.” See, e.g., Ann Robinow, The Potential of
Global Payment: Insights from the Field, COMMONWEALTH FUND, at 3 (2010); Zirui Song,
Dana Gelb Safran, Bruce E. Landon, Mary Beth Landrum, Yulei He, Robert E. Mechanic,
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health system to cover the total expected health care costs of a defined population
for a given time period.301 A health system that exceeds its global budget must make
up for the excess spending in the following year’s budget, but if its expenditures
come in under budget, the health system keeps the surplus.
CMS has modified Maryland’s rate setting waiver to require implementation of
global budgets.302 Other states could similarly establish regulatory limits on hospital
budgets without first implementing stand-alone rate setting. Controlling a provider’s
total revenues simultaneously constrains both prices and utilization because the provider’s revenues are the result of a combination of its prices, utilization, and operating costs. A global budget approach tied to population health spending may be more
efficient than stand-alone hospital rate setting because providers cannot simply increase utilization to make up for constrained prices, increase prices to compensate
for constrained utilization, or cost shift between inpatient and outpatient settings.
Vermont passed legislation in 2012 to constrain total health care spending through
administrative review of hospital budgets. 303 Hospitals are required to submit their
proposed annual budget to the state’s Green Mountain Care Board for review and
approval.304 The Board may require a hospital to adjust its budget with changes to its
rates or net revenues,305 and hospital compliance with the budget is enforceable
through court-ordered injunction or civil administrative penalties.306 Vermont is
moving toward a global budget system, which would allow the Board to set payments
rates and total revenues for hospitals from all payers to manage all of the health care
for a given population.307 Under the global budget system, the Board would set a
uniform rate increase for each hospital applicable to all payers, eliminating the

Matthew P. Day & Matthew E. Chernew, The ‘Alternative Quality Contract,’ Based on a
Global Budget, Lowered Medical Spending and Improved Quality, 31 HEALTH AFF. 1885,
1885–86 (2012).
301. See Song et al., supra note 300, at 1885.
302. Maryland All-Payer Model Agreement, CMS–Md., Feb. 11, 2014, http://mhcc
.maryland.gov/mhcc/pages/hcfs/hcfs_hospital/documents/chcf_all_payer_model_agreement
.pdf [https://perma.cc/UJ6D-B9US] (setting forth CMS’s 2014 Medicare innovation waiver
for Maryland’s all-payer model, including limits on total hospital revenues); see generally,
Maryland All-Payer Model, CTRS. FOR MEDICARE & MEDICAID SERVS. (Feb. 6, 2015),
https://innovation.cms.gov/initiatives/Maryland-All-Payer-Model/ [https://perma.cc/325V-LKZC].
303. VT. STAT. ANN. tit. 18, § 9456 (West 2012 & Supp. 2015); 4-7 VT. CODE R.
§§ 3:3.100–3.3.500; see generally Green Mountain Care Bd., The Green Mountain Guide to
Hospital Budget Review (2012), http://gmcboard.vermont.gov/sites/gmcb/files/files/hospital
-budget/GMCB-Hospital-Budget-Review-Guide.pdf [https://perma.cc/T4WR-MUYQ].
304. VT. STAT. ANN. tit. 18, § 9456(a)–(d) (West 2012 & Supp. 2015); 4–7 VT. CODE R.
§ 3:3.300.
305. 4-7 VT. CODE R. § 3:3.400.
306. VT. STAT. ANN. tit. 18, § 9456(h) (West 2012 & Supp. 2015).
307. Zack Budryk, VT Hospitals Eye “Global Budget” Payment Model, FIERCE
HEALTHCARE (Apr. 15, 2014), http://www.fiercehealthfinance.com/story/vt-hospitals-eyeglobal-budget-payment-model/2014-04-15 [https://perma.cc/3XUS-7L8L]; Morgan True,
Vermont To Launch Global Budget Pilot for Hospitals, VT DIGGER (Apr. 14, 2014),
http://vtdigger.org/2014/04/14/vermont-launch-global-budget-pilot-hospitals/.
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hospital’s separate rate negotiation with each commercial payer. 308 In late 2016,
CMS and Vermont agreed to implement an all-payer model, which aligns payment
rates for Medicare, Medicaid, and commercial payers under an all-payer accountable
care organization.309 Under the all-payer model, which not only applies to hospital
services but also includes physician and other ancillary providers, Vermont will limit
statewide per-capita health spending growth to 3.5% annually and move away from
a fee-for-service payment model to payments that are adjusted for population health
outcomes and quality of care targets.310
Initial results from Maryland and Vermont’s efforts at hospital budget oversight
are promising. During the first year with global budgets, Maryland limited per capita
hospital cost growth to 1.47%—well under the target of 3.58% annual growth—and
saved Medicare $116 million. 311 Vermont’s hospitals have been limited to modest
budget increases, but they simultaneously increased their profitability.312 Global
budget models are promising because they go beyond rate setting models that focus
only on prices to incorporate mechanisms to oversee all the components of total
health care spending: prices, utilization, and hospital operating costs.
The primary advantage of all forms of provider rate regulation is that these approaches directly counteract providers’ pricing power in noncompetitive markets.
Rate regulation does this either through administrative rate setting as is done by

308. Richard Slusky, Spenser Weppler & Robert Murray, Green Mountain Care Bd.,
Proposed Pilot Payment Reform Projects: Consideration of Hospital Global Budget Pilot, VT.
GEN. ASSEMBLY, at slide 8 (Apr. 3, 2014), http://legislature.vermont.gov/assets/Documents
/2014/WorkGroups/House%20Ways%20and%20Means/Health%20Care/W~Robert%20Murray
%20and%20Richard%20Slusky~Proposed%20Pilot%20Payment%20Reform%20Projects
%20Consideration%20of%20Hospital%20Global%20Budget%20Pilot~4-3-2014.pdf
[https://perma.cc/F45Q-5QVE].
309. Vermont All-Payer Accountable Care Organization Model Agreement, CMS–Vt.,
Oct. 27, 2016, http://gmcboard.vermont.gov/sites/gmcb/files/documents/10-27-16-vermont
-all-payer-accountable-care-organization-model-agreement.pdf [https://perma.cc/D6MR-JRHV];
see also, Green Mountain Care Board of Vermont, In re: Vermont All-Payer Accountable Care
Organization Model Agreement (Oct. 31, 2016), http://gmcboard.vermont.gov/sites/gmcb
/files/documents/APM-FINAL-Justification.pdf [https://perma.cc/WZH9-5F3Z] (describing
the Board’s justification for entering into the all-payer-model agreement with CMS).
310. See Vermont All-Payer ACO Model, CTRS. FOR MEDICARE & MEDICAID SERVS. (Oct.
26, 2016), https://innovation.cms.gov/initiatives/vermont-all-payer-aco-model/ [https://perma.cc
/3MDQ-XFQE].
311. Ankit Patel, Rahul Rajkumar, John M. Colmers, Donna Kinzer, Patrick H. Conway &
Joshua M. Sharfstein, Maryland’s Global Hospital Budgets—Preliminary Results from an AllPayer Model, 373 N. ENG. J. MED. 1899, 1899 (2015).
312. See Nancy Remsen, Hospitals in Vermont Anticipate Modest Budget Increases Next
Year, SEVEN DAYS (July 23, 2015), http://www.sevendaysvt.com/OffMessage/archives/2015
/07/23/hospitals-in-vermont-anticipate-modest-budget-increases-next-year [https://perma.cc
/5RBM-CYR6] (reporting that the Chair of the Green Mountain Care Board, Al Gobeille,
noted that the average rate increase Vermont hospitals requested from insurers was only 4.3%,
the lowest rate increase in fifteen years); see also Erin Mansfield, Special Report: Despite
Regulation, Hospital Profits Up, VT DIGGER (July 17, 2016) http://vtdigger.org/2016/07/17
/special-report-despite-regulation-hospital-profits-up/ [https://perma.cc/9A76-JUJH].
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public utilities and in the Medicare program or by combining the bargaining power
of all purchasers and payers. Rate regulation also has the potential to dramatically
reduce administrative costs for providers. By eliminating price discrimination among
payers, providers could reduce the administrative costs of negotiating different rates
and maintaining separate billing procedures for each payer. These administrative
costs are significant drivers of health care costs as the United States’ fragmented
payer landscape explains much of why providers’ administrative costs are so much
higher in the United States than in other countries with similarly developed health
systems.313 To maximize transparency and administrative ease, the rate schedule
could be based on Medicare rates, and to the extent that Medicare is not included in
the payment system, the rate setting entity could express private rates as a simple
multiplier of Medicare rate.
Rate setting could allow prices to vary between providers, but the variation in
price would reflect differences in quality rather than market power as it does now.314
Thus, under a rate-setting regime, you could still have an element of competition
between providers on the basis of value and quality or services offered.
One of the biggest challenges of rate setting is political. The major hospital systems whose prices would be constrained the most are often extremely powerful entities, the engines of local economies and jobs. A lesson from the many states that
implemented and later abandoned rate setting in the 1980s is that the rate-setting
agency must be structured to avoid regulatory failure from bureaucratic complexity
and regulatory capture.315 Regulatory complexity and inflexibility can be avoided by
using standard payment formulas rather than individual budget review.316 A global
budget approach may also get regulators out of the difficult business of setting specific rates for each item and service and instead let them focus on total hospital budgets, which may be more flexible and less complex. Ensuring the independence of the
rate setting authority from excessive industry or political influence is essential to
avoiding regulatory capture. Agency independence can be protected by prohibiting
commissioners from having affiliations with regulated providers 317 and

313. David U. Himmelstein, Miraya Jun, Reinhard Busse, Karine Chevreul, Alexander
Geissler, Patrick Jeurissen, Sarah Thomson, Marie-Amelie Vinet & Steffie Woolhandler, A
Comparison of Hospital Administrative Costs in Eight Nations: US Costs Exceed All by Far,
33 HEALTH AFF. 1586, 1589, 1592 (2014) (explaining that U.S. hospitals spend more than 25%
of all costs on administration, driven by the complexity of the reimbursement system and the
mode of capital funding).
314. COMMONWEALTH OF MASS. HEALTH POLICY COMM’N, 2015 COST TRENDS REPORT:
PROVIDER PRICE VARIATION 14–15 (2015), http://www.mass.gov/anf/budget-taxes-and
-procurement/oversight-agencies/health-policy-commission/publications/2015-ctr-ppv.pdf
[https://perma.cc/ZCH7-3L8Q] (noting that price variation under Maryland’s value-based
factors is substantially less than the variation in Massachusetts, which is driven largely by
provider market power); MURRAY & BERENSON, supra note 294, at 10–11.
315. MURRAY & BERENSON, supra note 294, at 72–73.
316. Id.
317. West Virginia’s Health Care Authority, for example, is an autonomous body within
the state’s Department of Health and Human Resources, and it is made up of three full-time
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implementing accountability measures, such as federal oversight under a Medicare
waiver, to counteract local political pressure to loosen standards or make special
exceptions.318
Another significant challenge with rate setting is that it only addresses the price
half of the cost-control equation.319 Rate regulation must be paired with global
budgets, volume adjustments, or other population-based payments to control the tendency to increase utilization. Both Maryland and West Virginia demonstrated that
rate setting can control costs-per-case quite effectively, but not volume. Maryland’s
2014 Medicare waiver adds global budgets to its rate-setting program, which is no
easy feat, but it is a necessary adjustment to control both the price and utilization
components of health care spending. Vermont’s all-payer model builds on an ACO
design, in which the ACO will receive a population-based payment for every person
attributed to it, whether a Medicare beneficiary or privately insured patient. 320
In sum, in states where competition is no longer functioning to keep provider
prices in check, rate regulation may be the preferred strategy, or the last best hope
for counteracting the price effects of health care integration. To set rates or global
budgets, provider rate regulation must be built on a foundation of information from
an APCD or similarly comprehensive and detailed claim data. The ingredient of independence is necessary to avoid regulatory failure from capture by powerful
providers.
CONCLUSION
Bending the health care cost curve requires constraining both utilization and price.
Reducing fragmentation in health care can help reduce overutilization by offering
incentives to promote collaboration and integration. But increased health care integration is a double-edged sword. Efforts to integrate health care to achieve benefits
in terms of quality and reduced utilization can also lead to increased market power
and prices, which could potentially defeat much or all of the cost savings from reduced utilization.
There are currently few systemic checks on the growing pricing power of integrated health care providers. Federal antitrust and cost-control policies are limited in
their abilities to control private health care price increases, particularly new forms of
vertical integration driven by health reforms like ACOs. This creates both an opportunity and an obligation for states to address rising prices stemming from health care
integration and consolidation.
The way to manage the double-edged sword of health care integration is to encourage beneficial integration but pair it with oversight on price and quality. States

board members who cannot have financial or employment relationships with any hospital or
health care organization. Id. at 31.
318. Id. at 73–74.
319. See Mark Pauly & Robert Town, Maryland Exceptionalism? All-Payers Regulation
and Health Care System Efficiency, 37 J. HEALTH POL. POL’Y & L. 697, 699 (2012); Kevin
Outterson, All-Payer Rate Setting in JAMA: A “Maryland Miracle”?, INCIDENTAL ECONOMIST
(Sept. 14, 2011), http://theincidentaleconomist.com/wordpress/all-payer-rate-setting-in-jama
-a-maryland-miracle/#comments [https://perma.cc/GH5D-HS7G].
320. See Green Mountain Care Bd., supra note 303, at 5–6.
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have a menu of policy options, and the particular policy recipe will vary by state, but
three ingredients are necessary for effective oversight: (1) Information—states must
have a means to collect and analyze price, quality, utilization, and market data, such
as an all-payer claims database, in order to determine which policy choices to select
and to evaluate their success; (2) Independence—state oversight bodies must be insulated from the powerful providers they oversee; and (3) Regulatory Authority
—state oversight bodies must have the authority to enforce or impose limits on
providers’ prices when they become too high. If we are to control our personal and
national health care spending, states have a critical role to play in overseeing health
care integration and private health care price increases.

